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3Summary
A ventilated perfused rat lung model is described enabling simultaneous measurement 
of pulmonary perfusion pressure (PPP), lung weight (LW) and pulmonary inflation 
pressure (PIP). This model was stable for 2 h. Phenylephrine selectively increased PPP, 
carbachol selectively increased PIP whereas bradykinin (BK) caused increased PPP, 
LW and PIP. Low doses of BK caused reversible increases in LW. Higher doses caused 
irreversible increases in LW which were associated with albumin accumulation. 
Manipulation of venous outflow pressure, retrograde perfusion and the vasodilator 
papaverine revealed that the changes in LW were explicable as sequelae of vascular 
hydrostatic pressure changes.
Endothelin (ET) receptors were also characterised in orthogradely and retrogradely 
perfused lungs. Determination of agonist potency profiles and use of ET receptor 
antagonists showed that ETb2 receptors are located arterially whereas ETA receptors are 
predominantly venous in distribution. The bronchoconstrictor actions of ETs and 
SX6C suggest the presence of ETB receptors in the bronchial smooth muscles. Results 
also suggest the possibility of heterogeneity of ETA and ETb receptor subtypes.
Pulmonary actions of ET-1 and SX6C were augmented by L-NOARG suggesting that 
these substances stimulated the release of nitric oxide (NO) which subsequently 
attenuated their bronchoconstrictor effects. When the vascular tone was elevated, ET-1, 
ET-3 and SX6C produced ETBi receptor-mediated pulmonary vasodilation as indicated 
by the potency profile, and the effects of ET antagonists. The vasodilator responses to 
ET-1 are mediated by the release of NO. In addition to NO, prostaglandins also 
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9An understanding of biological processes at different levels will be needed to provide 
answers to many questions concerning diseases of humans. An early molecular biologist, 
Albert Szent-Gyorgyi (1963) wrote in his article entitled “ The Promise of Medical 
Science", which appeared in Man and His Future:
One important point I  overlooked was "organization". Organization 
means if  nature puts two things together in a meaningful way, 
something new is generated, when I take two things apart, I  have 
thrown away something, something which has been the very essence o f 




1 1 The structure of the lung
1.1.2 Airways
The lungs are situated bilaterally within the thorax, and separated from each other by the 
heart. The structure of the lung has been reviewed by many investigators (Levitzky,
1982; Carola et al., 1990; Vander et aL, 1990a; Tyler and Julian, 1992). Briefly, each 
lung has an apex that lies in the plane of the thoracic inlet and a base which rests upon 
the convex surface of the diaphragm. The left lung is divided into two lobes, superior and 
inferior and the right lung in humans is divided into three lobes, superior, middle and 
inferior. However, the right lungs from laboratory mammals have four lobes: cranial, 
middle, caudal and accessory (the terms cranial and caudal are given for superior and 
inferior lobes respectively in all common animals). The conducting zones of the lung 
include the trachea and extra pulmonary bronchi and various orders of small 
intrapulmonary bronchi (Figure 1). The bronchi continue to branch into smaller and 
smaller tubes called bronchioles and then terminal bronchioles which after repeated 
branching finally end in a number of respiratory bronchioles consisting of alveolar ducts 
that lead into microscopic air sacs called alveoli. The whole systems look so much like an 
inverted tree that it is commonly called the "respiratory tree".
The alveolar surface of the lung is lined with a continuous sheet of epithelial cells 
referred to as type 1 and type 2 epithelial cells. Type 1 epithelial cells cover > 90 % of 
the alveolar surface which provide a large surface for gas exchange and also serve as a 
permeability barrier. Type 2 cells secrete a surfactant which helps to keep alveoli inflated. 





























alveolar sacs 8 X 10'
Figure 1 Schematic representation of airway branching and approximate numbers of 
tubes in each branch. Modified from Levitzky, (1982); Vander et al., (1990a).
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1.1.2 Pulmonary vasculature
The lung has two separate blood supplies the pulmonary and bronchial circulations 
respectively. These circulations are different in size, origin and function and are described 
as follows:
(a) Pulmonary circulation
The main pulmonary artery divides into two branches which supply the right and left 
lung. The pulmonary arteries and arterioles run along the bronchi, bronchioles, and 
alveolar ducts. Arteries less than 100 pm in diameter lose their muscular coat and 
become capillary in structure, 60% of vessels 32-48 pm in diameter are non-muscular 
(see Snashall and Hughes, 1981). The capillaries arise as side branches or terminations of 
the arterioles, lying in the alveolar septa and separated from the alveolar space by a small 
amount of interstitial tissue and the alveolar lining cells. The capillaries are suspended in 
air which encourages gas exchange. However, this can predispose the lung to oedema 
formation when capillary pressures are increased (Efffos, 1984). The alveolar capillaries 
drain into vessels which are histologically identical to the arterioles, and then into 
pulmonary veins which tend to be situated away from the bronchial tree. Finally, the 
large pulmonary veins pursue an independent course towards the hilum of the lung. The 
pulmonary veins drain into the left atrium.
(b) The Bronchial circulation
The bronchial circulation is also known as the "pulmonary collateral circulation", or the 
"systemic blood supply to the lungs" (Deffebach et al., 1987). This circulation is unique 
in that the arteries arise from the systemic circulation i.e. from the aorta, subclavian, 
internal mammary, and intercostal vessels, whilst the venous components drain into the 
pulmonary system.The bronchial artery is considered the nutrient artery supplying the 
bronchi, hilar lymph nodes, and vasa vasorum to the pulmonary arteries and pulmonary 
veins (Kay, 1992). Both the bronchial and pulmonary circulations communicate freely 
with each other on the arterial and venous sides. An examination of the distribution of 
bronchial arteries in 11 mammalian species including humans and rat found anastomoses
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between the bronchial and pulmonary arteries in all species, except the pig, dog, cat, and 
rhesus monkey (McLaughlin et al., 1966; McLaughlin 1983). There are two distinct 
types of bronchial veins; the deep or true veins which are intrapulmonaiy vessels related 
to the bronchi and which drain into the pulmonary veins or direct into the left atria. The 
second group of bronchial veins drain the subpleural and hilar structures into the azygos 
veins (Marchand et al., 1950). The relationships between the bronchial and pulmonary 
circulations are shown in Figure 2.
1.1.3 Lymphatic drainage o f the lung
Lymphatic channels are present in the interstitial space. The first group of lymphatics 
originates in the visceral pleura or in the interlobular septa, draining the periphery of the 
lung lobules by channels that follow the course of the pulmonary veins to the hilum of 
the lung. The second group of lymphatics begin as blind-ended tubes in the acini around 
the alveolar ducts, draining to the hilum via the peribronchial lymphatics. Normally, the 
lymphatics of the upper part of the left lung drain into the thoracic duct while those from 
the remainder of the lung and from the whole of the right lung drain into the right 









Figure 2 Schematic of the blood supply to the lung, showing the relationship between 
the bronchial and pulmonary circulations. The pulmonary artery supplies the pulmonary 
capillary network (A). B represents the bronchial arterial supply to the walls of the 
pulmonary artery (vaso vasorum). C is the bronchial artery supply to the airways. 
Network D represents the bronchial capillary supply to most of the bronchi; these vessels 
drain into the pulmonary veins. Network E represents the bronchial capillary supply that 
anastomoses with the pulmonary capillaries and drains into the pulmonary veins. The 
bronchial veins drain into the vena azygos, or intercostal veins. Shaded areas represent 
blood of low O2 content. Arrows indicate the direction of the blood flow.
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1.2 Regulation of pulmonary vascular tone
The pulmonary blood vessels are particularly suited to maintain a delicate balance of 
pressure and distribution of flow that optimizes gas exchange. In normal mature 
mammals, the pulmonary circulation is a low pressure, high flow, low-resistance system 
and pulmonary arterial pressure is normally about one-sixth that of the systemic arterial 
pressure (Kay, 1992). The pulmonary blood vessels are capable of being distended, 
narrowed, or collapsed, as well as actively constricting and dilating. Pulmonary vascular 
smooth muscle is responsive to both neural and humoral influences. These influences 
produce active alterations in pulmonary vascular resistance, as opposed to passive 
factors such as gravity. The factors which can affect pulmonary vascular tone are given 
below.
12.1 Neural control
The autonomic nerve fibres are found in close association with pulmonary blood vessels 
(Zorychta and Richardson, 1992). The elastic pulmonary artery has the highest density of 
innervation whereas it diminishes toward the periphery. However, the pulmonary veins 
are devoid of any autonomic control. Sympathetic activation causes an increase in 
pulmonary vascular resistance which is primarily mediated by -adrenoceptors whereas 
p-adrenergic receptor activation produces pulmonary vasodilation (Hyman et al., 1981; 
Hyman et al., 1990). Retrograde and orthograde perfusion of dog lungs has shown that 
arteries are the major site of the vasoconstrictor response to sympathetic nerve 
stimulation (Daly et al., 1970).
The pre-ganglionic cholinergic efferent nerve fibres pass down the vagus nerve into the 
lungs. The extra-pulmonary arteries and large pulmonary veins of rat contain 
acetylcholinestrase positive nerve fibres, whereas they are absent in intra-pulmonary 
arteries of the rat (El-Bermani, et al., 1970). Investigators have reported that vagal
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stimulation produces variable responses in different species depending upon the 
pulmonary vascular tone; that is, under low basal tone it caused vasoconstriction, but 
when the tone was raised, vagal stimulation caused vasodilation. Heterogeneous 
muscarinic receptors have been identified. Muscarinic receptors mediating vasodilation in 
the pulmonary vascular bed are of the M3 sub-type (Post et al., 1991).
The neural mechanisms that are not inhibited by adrenergic or cholinergic blockade are 
attributed to transmitter release from non-adrenergic non-cholinergic (NANC) fibres. 
NANC mediated relaxation in pulmonary arteries is reduced by nitric oxide synthase 
inhibitors, providing evidence that nitric oxide is a NANC neurotransmitter (Liu et al., 
1992). This neural mechanism may play a role in the regulation of pulmonary vascular 
tone (for review see Barnes and Liu, 1995).
1.22 Humoral control and role of the endothelium
The pulmonary vasculature responds actively to many humoral and autocoid factors. 
Many vasoactive substances circulating in the blood or which are synthesised by the lung 
can affect pulmonary vascular resistance. For instance, endogenous angiotensin-2 
produces vasoconstriction, bradykinin is potent in releasing nitric oxide (Palmer et al., 
1987) and also stimulates prostacyclin release (Peers and Hoult, 1986; Ignarro et al.,
1987). Bradykinin play an important role in the regulation of vascular tone and two types 
of bradykinin receptors BKi, BK2 have been found in pulmonary vascular smooth muscle 
(Regoli et al., 1986). Other vasoactive substances which can influence pulmonary 
vascular tone are substance P, vasoactive intestinal peptide (VIP), calcitonin gene- 
related peptide (CGRP), atrial natriuretic peptides (ANP), 5-hydroxytryptamine, 
eicosanoids, histamine and platelet activating factor (for review see Barnes and Liu, 
1995).
Endothelial cell-derived mediators also play an important role in the regulation of 
pulmonary vascular tone by synthesizing and releasing endothelin (Yanagisawa et al.,
1988), prostacyclin (Moncada et al., 1976) and endothelium -derived relaxant factor 
(EDRF), now widely accepted to be nitric oxide (Palmer, et al., 1987). Basal and
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stimulated nitric oxide both participate in the maintenance of low pulmonary vascular 
tone (Liu and Barnes, 1994; Barnes and Liu, 1995) and the localisation of nitric oxide 
synthase has been reported in the pulmonary arterial and bronchial vessels in rat (Xue et 
al., 1994). Endothelium-derived hyperpolarizing factor (EDHF) has also been shown to 
be a determinant of vascular calibre under normal conditions, and may therefore be 
important in the regulation of vascular resistance (Garland et al., 1995).
1.3 Regulation of airwav tone:
1.3.1 Neural control
The airways are supplied by nerves, derived from the sympathetic and parasympathetic 
nervous systems, and by sensory nerves that originate from the sensory ganglia of the 
vagus nerve. The sensory fibres terminate on the bronchi and are responsible for 
carrying the impulses from irritant and stretch receptors in the lung to the central nervous 
system (Said, 1989; Matthew and Altura, 1990; Barnes, 1992). The vagal 
parasympathetic fibres produce bronchoconstriction via activation of the muscarinic 
receptor. The nerve fibres from thoracic sympathetic ganglia produce bronchodilation. 
Both a  - and (3 - adrenoceptor subtypes have been shown to be present on the bronchial 
smooth muscles (Kneussl and Richardson, 1978; Rugg et al., 1978).
Neuropeptides that may influence airway smooth muscle function include; ANP, 
bombesin, CGRP, VIP, substance P, neurokinins A and B (reviewed by Said, 1989).
The majority of peptides with activity on airway smooth muscle are bronchoconstrictor 
such as bombesin, CGRP, neurokinins. The peptides that relax airway smooth muscle 
make up a shorter list i.e. VIP, ANP etc. (see Said, 1989). In addition, a third 
component in the neural control of respiratory smooth muscle is NANC transmission. 
Linden et al., (1992) showed that NANC responses can counteract changes in airway 
smooth muscle tone via a contraction or a relaxation depending on the tone prior to 
activation. Tucker et al., (1990) have shown that nitric oxide is invoved in mediating 
NANC relaxations produced by electrical field stimulation in the guinea pig trachea.
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NANC relaxations have been observed in airways isolated from a large number of 
species, including human (for review see Ellis and Undem, 1994).
1.3.2 Humoral regulation and role o f airway epithelium
The epithelium plays an important role in modulating the responsiveness of the 
underlying smooth muscle. The mediators released from the epithelial cells include 
leukotrienes B4, C4, and prostaglandins D2 , E2, and F2a (see review by Davies and 
Devalia,1992; Delamere et al., 1994). There has also been considerable interest in the 
possibility that relaxant factors can be released from airway epithelial cells. Barnes et al., 
(1985) reported that the tracheobronchial epithelium may release one or more factors 
promoting airway relaxation. Pharmacological evidence has shown that one of the 
epithelium-derived relaxing factors might be nitric oxide, for example in guinea pig, the 
epithelium-dependent tracheal relaxation has been shown to be blocked in the presence 
of nitric oxide synthase inhibitors (Folkerts et al., 1995). The epithelial cells appear to 
have both constitutive and inducible forms of nitric oxide synthase (Hamid, et al., 1993; 
Xue, et al., 1994; Guo, et al., 1995) and the localisation of nitric oxide synthase enzyme 
has been reported in airway epithelium in rat lung (Xue et al., 1994). Nitric oxide 
synthases are found in a variety of other cell types in the lung such as macrophages, 




The most well known function of the lungs is that of respiration. Gas exchange between 
air and blood is the joint function of the alveoli and the networks of blood capillaries that 
envelop them. The capillaries provide an enormous surface area, making possible an 
extremely rapid diffusion of gasses between alveolar air and pulmonary capillary blood. 
The calculated number of alveoli in human lung (body weight 74 kg) are 950 million 
(Volberg and Blanchard, 1992) There may be as many as 280 billion pulmonary
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capillaries, or nearly 1000 pulmonary capillaries per alveolus (Levitzky, 1982). It has 
been estimated that if the alveoli could be opened up flat, they would form a surface area 
about the size of a tennis court; that is about 85 square meters or well over 40 times the 
surface area of the entire body (Thibodean and Patton, 1993).
1.4.2 Non -respiratory
The other functions of the lung are non-respiratory functions. The pulmonary circulation 
receives the entire cardiac output and within the pulmonary vasculature, blood is 
exposed to a huge capillary endothelial surface. The vascular endothelial cells synthesise 
an apparently ever-growing number of physiologically important molecules. In part these 
substances are secreted into the blood or directed towards the subendothelial matrix. 
These characteristics make the pulmonary microcirculation uniquely suited for exercising 
a controlling influence on blood-borne vasoactive hormones. Vane, (1969) proposed that 
the lung should be considered as an endocrine organ owing to its capability to regulate 
the amounts of vasoactive materials reaching the arterial circulation. The lung can 
activate, inactivate, synthesize, and release a variety of biologically active compounds 
which are briefly summarised in table 1.
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Table 1 Mediators which are metabolised or released by the lung:
(a) Activation
Angiotensin-I to angiotensin-II (Ng and Vane, 1967)
Big endothelin-1 to endothelin-1 (Hisaki et al., 1994b)
(b) Inactivation
Serotonin (Alabaster and Bakhle, 1970)
Bradykinin (Alabaster and Bakhle, 1972; Bakhle, 1977; Pesquero et al., 1992; Baker 
et al., 1992)
Prostaglandins E 1? E2, F2a  (Piper etal., 1970)
Endothelin-1 (Westcott etal., 1990; Sirvio et al., 1990)
Norepinephrine (Bryan-Llukaetal., 1992)
(d) Synthesis or release o f vasoactive agents
Histamine (Martins et al., 1991)
Substance P (Martins et al., 1991)
Prostaglandins, I2, F2a (Palmer et al., 1973; Robinson and Hoult, 1980; Korbut et 
al., 1981)
Endothelin-1 (Vemulapalli etal., 1992)
The processes outlined in the table above are designed to regulate the concentrations of 
agents such as prostaglandins, amines and peptides in the blood before they reach the 
systemic circulation. In addition to their actions at non-pulmonary sites, these hormones 
can also change intrapulmonary blood flow and airway tone through their effects on 
vascular and bronchial smooth muscle; therefore, mechanisms for terminating such 
effects in the lung assume considerable interest.
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1.5 Lung diseases
1.5.1 Pulmonary vascular diseases
(1) Pulmonary hypertension: Pulmonary hypertension is defined as an increase in 
pulmonary vascular pressure and this often leads to right ventricular hypertrophy and 
ultimately heart failure. Chronic pulmonary hypertension is a progressive disease of the 
pulmonary vascular wall. The histological changes that occur in the pulmonary 
vasculature are swelling, hypertrophy and hyperplasia of the cells in the intima and the 
medial coat of the pulmonary arteries leading to narrowing of the lumen. There is also an 
extension of the smooth muscle cells into non-muscular pulmonary arteries (see Matthew 
and Altura, 1990). Some of the important features of pulmonary hypertension are 
hypoxaemia, pulmonary oedema and bronchoconstriction (Matthew and Altura, 1990; 
Weitzenblum, 1994). The other clinically distinct syndromes of pulmonary hypertension 
are:
(a) Primary pulmonary hypertension; This is characterised by elevated pulmonary 
arterial pressure in the absence of primary cardiac or parenchymal pulmonary disease. It 
affects small pulmonary arteries, in which proliferative lesions involving endothelial and 
smooth muscle cells, obstruct flow. This damage leads to alterations in pulmonary 
vascular smooth muscle content resulting in exaggerated pulmonary vasoconstriction. 
Deranged vasodilating mechanisms appear inadequate to oppose vasoconstriction caused 
by lung injury and associated hypoxia. Recent evidence suggests that endothelial 
dysfunction plays a key role in causing chronic hypoxic pulmonary hypertension 
observed in humans and in animal models of pulmonary hypertension (Liu and Barnes, 
1994; Barnes and Liu, 1995). Right ventricular dysfunction and pulmonary vascular fluid 
leakage with resultant interstitial oedema are common clinical sequelae as summarised by 
Wilson et al., (1992).
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(b) Secondary pulmonary hypertension; Elevated arterial pressure in the pulmonary 
circulation may be secondary to chronic lung diseases, including chronic bronchitis, 
emphysema, bronchiectasis, cystic fibrosis, etc (Wilson et al., 1992). Pulmonary 
hypertension associated with an increase in pulmonary vascular resistance is frequently 
observed in patients with adult respiratory distress syndrome (ARDS).
(2) Pulmonary oedema
Oedema in the pulmonary circulation continues to be a major cause of morbidity and 
mortality in critically ill patients suffering from pulmonary hypertension (Cope et al., 
1992). Pulmonary oedema is a pathologic state in which there is abnormal extravascular 
water storage in the lung (Visscher et al., 1956). Normally, a small amount of fluid 
containing plasma proteins filters out of the blood stream into the pulmonary interstitial 
space. The lymphatic system then drains this fluid into the systemic veins. When capillary 
filtration increases, the flow of fluid and proteins into the interstium can eventually 
exceed the maximal removal rate by the lymphatics, and the intersitium begins to swell. 
When the interstitial water exceeds the interstitial space capacity, fluid seeps into the 
alveoli (Cope et al., 1992). The factors affecting liquid movement from the pulmonary 
capillaries is shown in Figure 3.
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Figure 3 Schematic illustration of the factors affecting liquid movement from the 
pulmonary capillary. Pcap = capillary hydrostatic pressure; Pis = interstitial hydrostatic 
pressure; 7tpi = plasma colloid osmotic pressure; 7tis = interstitial colloid osmotic 
pressure. (Pis is assumed to be negative).
The conditions that can produce pulmonary oedema may be summarised as: (a) an 
increase in permeability of capillary endothelium, (b) an increase in capillary hydrostatic 
pressure or decrease in colloid osmotic pressure, (c) decrease in interstitial hydrostatic 
pressure or increased interstitial colloid osmotic pressure, (d) lymphatic insufficiency 
(Levitzky, 1982). In the pulmonary circulation plasma colloid osmotic pressure is usually 
greater than capillary hydrostatic pressure, therefore there is very little bulk fluid 
movement out of the capillary (see Vander et al., 1990b).
In addition, Staub (1974) suggested three pathways that can be taken by water and 
solute molecules to cross membrane: (a) across cell membranes, (b) through intracellular 
junctions, and (c) by non selective leak. As shown in Figure 4 the pores crossing cell 
membranes (arrow 1) are water-filled channels of 4-5 A° radius and only allow water
diffusion and flow but are highly restrictive to the movement of solute molecules due to 
size. The chief site of ultrafiltration and protein flow is probably via the intracellular 
junctions. Arrow 2 shows the intracellular junctional pores which have a pore radius too 
small for plasma protein molecules to penetrate. Arrow 3 indicates the intracellular 








Figure 4 Schematic representation of the fluid and protein exchange features of the lung. 
There are three extracellular compartments; microvascular lumen, interstitium including 
lymph capillaries, and alveolar gas space. The three routes of passive transport are:




Asthma was first described by Hippocrates in the fourth century BC and its name derives 
from the Greek word for panting (meaning; swift and shallow breathing with a fast 
respiratory frequency and small tidal volume) described by Wardlaw, (1993). Although, 
medical advances of the nineteenth and twentieth centuries have established asthma as a 
diagnostic entity, it is recognised that this disease is heterogeneous and difficult to 
classify. Jacobs and Kaliner, (1989) stated that asthma can be defined clinically as a 
recurrent disease causing intermittent wheezing, breathlessness, and cough with sputum 
production. Barnes et al., (1992) described asthma as a clinical syndrome characterised 
by increased responsiveness of the tracheo- bronchial tree to a variety of stimuli and 
variable airflow obstruction caused by a combination of oedema, smooth muscle spasm 
and mucous plugging, which in turn are due to airway inflammation. Allergy is the most 
frequent cause of asthma, accounting for 90 % of asthmatics and the mediators derived 
from the mast cells play a pivotal role (Jacobs and Kaliner, 1989). The other causes of 
asthma include respiratory tract infections and enironmental pollution.
1.6 Methods used to investigate lung function
1.6.1 Isolated pulmonary tissues
Lung function can be studied by using isolated pulmonary tissues in a conventional 
organ bath and pulmonary vascular smooth muscle reactivity to many vasoactive agents 
has been studied both in human and animal tissues by using rings or strips of pulmonary 
blood vessels (McKay et al., 1991; La Douceur et al., 1993; Buchan et al., 1994; 
MacLean et al., 1994; Maguire and Davenport, 1995). Despite the fact that vasoactive 
agents can produce selective actions on venous pulmonary smooth muscle, limited data is 
available from isolated pulmonary veins (Sudjarwo et al., 1993; Zellers et al., 1994; Gao 
et al., 1995a). Isolated tracheal or bronchial preparations have also been used (Maggi et 
al., 1990; McKay et al., 1991; Hulsmann and de Jongste, 1993; Nally et al., 1994; 
Yoneyama etal., 1995).
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Alternatively, investigations of the actions of agents which produce contractions of 
pulmonary vascular and airway smooth muscles have been carried out using lung 
parenchymal strips (Lulich et al., 1976; Lach et al., 1994). In this preparation thin strips 
are dissected from a lung lobe and studied in a conventional organ bath. Parenchymal 
strips have also been used to investigate the activation or degradation of blood-borne 
polypeptides such as endothelins, the plasma concentrations of which are regulated in 
the pulmonary circulation and are known to exert extremely potent vascular and 
bronchial actions (Battistini et al., 1995).
The practical advantage of using isolated pulmonary tissues is that, they are easy to 
prepare and only small pieces of tissue are needed. However, when using pulmonary 
blood vessels no information can be gained on the responses of the studied agents on the 
bronchial smooth muscles. When only tracheal or bronchial tissues are used no 
information can be collected for the actions of substances on pulmonary vascular smooth 
muscle. When lung parenchymal strips are used, it is assumed that the drug-induced 
effects in parenchymal strips reflect the responses of smooth muscle of small airways 
present in the bronchioles and alveolar ducts. However, the involvement of non-airway 
components such as vascular smooth muscle complicates interpretation of the results 
(Mirbahar and Byre, 1980). Moreover, the parenchymal strip preparations isolated from 
different regions of lung can respond in a quantitatively distinct manner to various 
pharmacological agents (Wong et al., 1992). Therefore, the anatomical complexity of the 
parenchymal strip restricts its value as a method to study small airway pharmacology.
1.62 Whole lung models
Lung function has been studied by perfusing lungs with homologous whole blood or 
physiological salt solution (Czartolomna et al., 1991; Rodman et al., 1992). Depending 
on the experimental design, the lung can be perfused with whole blood, plasma or a 
blood -and plasma-free physiological salt solution (Chang and Voelkel, 1991). Blood- 
perfused lungs closely resemble the in vivo state and are often used in the studies of 
hypoxic pulmonary vasoconstriction. However, this is costly, for example using rats
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about 8  to 1 0  ml of whole blood may be removed from each donor rat and for each 
perfused lung experiment approximately 30 ml of whole blood is required (Chang and 
Voelkel, 1991). In studies assessing the vascular actions of lipid mediators or measuring 
lung metabolism of eicosanoids, binding of the mediators or metabolites to plasma 
proteins and metabolism by blood cells may complicate the interpretation of results. This 
can be improved by using a single pass perfusion model, however, a very large volume 
of perfusate is required, making the use of whole blood impractical.
The single-pass isolated lung model perfused with a physiological salt solution offers 
several advantages to study lung function as;
(a) It lacks blood components and the associated complications mentioned above.
(b) The components of the pulmonary perfusate can be precisely regulated. Additionally, 
the lung can be easily lavaged or studied microscopically.
(c) There is strict control over perfusate flow, and the pulmonary arterial, venous , and 
microvascular pressures can be accurately measured. These data allow calculation of 
arterial and venous resistance changes in response to the experimental conditions.
(d) Lung oedema formation can be continuously monitored.
A variety of methods have been developed to perfuse lungs either in situ or in vitro 
(Levey and Gast, 1966; Kroll et al., 1986; Niemeier, 1984; Ryrfeldt et al., 1990; Uhlig 
and Wollin, 1994). Isolated perfused lungs have been used extensively to assess the 
metabolism of vasoactive agents and vascular reactivity and several reviews of isolated 
perfused lung preparations have been published in past years. Most of these have focused 
on metabolic and toxicological studies (Bakhle and Vane, 1974; Gill and Roth, 1976; 
Said, 1979; Gillis and Pitt, 1982; Chang and Voelkel, 1991).
Lungs perfused via the pulmonary artery have been utilised to study the release of 
vasoactive substances in response to infusions of a variety of substances (Bakhle and 
Vane, 1974; Said, 1979; Robinson and Hoult, 1980; Bakhle et al., 1985; Peers and
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Hoult, 1986). In another study the lungs were inflated via the trachea, which was then 
clamped off and lung perfused via the pulmonary artery for studying the release of 
substances (Conroy et al., 1992).
Lungs perfused via the pulmonary artery are widely used to study the pulmonary 
vasoconstrictor activity of injected agents, however, the actions of such agents on lung 
weight and respiratory smooth muscles have not been studied (Okpako, 1972; Raj et 
al., 1992; Perreault and Baribeau, 1995).
Lungs are extensively utilised to investigate the actions of agents on bronchial resistance 
i.e. the bronchoconstrictor effects of bradykinin have been studied without monitoring its 
vascular actions (Lou, 1993). Alternatively, effects of bradykinin on pulmonary vascular 
and bronchial resistance have been monitored, while the effects on vascular permeability 
were ignored (Kroll et al., 1986; Ryrfeldt et al., 1990).
Some permeability investigations have been carried out using cultured pulmonary arterial 
endothelial cell monolayers (Horgan et al., 1991; Rodman et al., 1992). However, an 
endothelial monolayer system derived from one circumscribed locus cannot represent the 
complete lung circulation which is an important aspect of vascular reactivity. Therefore, 
studies of mechanisms of injury and loss of membrane integrity have also employed the 
isolated perfused lung preparation to investigate permeability in a complete alveolar 
capillary membrane in a physiologically intact system (Czartolomna et al., 1991; Horgan 
et al., 1991). Studies on isolated lungs have also been performed to investigate actions of 
substances on pulmonary vascular resistance and microvascular permeability by initially 
inflating the lung via the trachea which was then clamped (Seale et al., 1991).
Ventilated perfused lung models have been utilised to investigate the effects of perfusate 
composition on oedema formation. In these studies development of gross pulmonary 
oedema was indicated by swelling and translucency of the pulmonary parenchyma and by 
the appearance of tracheal fluid (Fisher et al., 1980).
In recent years isolated lung models have been modified to allow simultaneous 
measurements of the actions of agents on pulmonary vascular and bronchial smooth 
muscles (Selig et al., 1993; Uhlig and Wollin, 1994). However, in many of these studies 
the perfusate was recirculated and no indication with regard to the effect of perfusion 
time on lung viability was given.
In summary, the models used which range from simple pulmonary blood vessels and 
bronchial strip preparations to complex ventilated and perfused lung preparations 
have contributed substantially to progress in understanding the pathophysiology of 
pulmonary diseases such as pulmonary hypertension, adult respiratory distress 
syndrome, asthma. However, the precise relationship between pulmonary 
vasoconstriction, oedema and increase in bronchial resistance are still not clear. In 
order to gain more insight into the mechanisms of lung disease and the development 
of potential beneficial therapeutic agents, adequate models are needed. The study of 
isolated perfused and ventilated lung tissue in which the normal relationship between 
the ventilatory and circulatory unit is preserved in vitro would be an important step in 
this direction.
Many of the studies mentioned above have shown that the lung can metabolise and 
produce numerous vasoactive agents including endothelins. These recently discovered 
mediators may have an important role to play in pulmonary and other disease states, 
and their actions have been one of the major subjects examined in this thesis. A brief 
introduction on the history of endothelins, endothelin receptors /  antagonists and their 
pathophysiological roles is given below.
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1.7 Endothelins
1.7.1 Discovery of endothelins
Investigations have confirmed that vasoactive products produced from endothelial 
cells are potent modulators of vascular smooth muscle contractility. Initially two 
unstable vasodilators were described, prostacyclin (Moncada et al., 1976) and 
endothelium-derived relaxing factor (EDRF) (Furchgott and Zawadski, 1980) later 
identified as nitric oxide (Palmer, et al., 1987). Hickey et al., (1985) reported the 
characterisation of a potent and stable peptidergic vasoconstrictor produced by 
cultured endothelial cells, originally termed endotensin or endothelium-derived 
constricting factor (EDCF). After confirmation of these findings EDCF was 
isolated, purified, sequenced, cloned and the molecule renamed as endothelin (ET) 
by Yanagisawa et al., (1988).
1.7.2 ET isopeptides
Analysis of human genomic sequences revealed the existence of three distinct 
genes for ET; these were named as ET-1, ET-2, and ET-3 (Figure 5). All family 
members contain 2 1  amino acid residues and show structural similarities, including 
four cysteine residues (positions 1,3,11, and 15), as well as similar amino acids in 
position 8 ,10, 20,21. In the ETs, all four cysteine residues participate in disulfide 
bonding (Cys^Cys15; Cys3-Cysu ) (Inoue et al., 1989). In addition, a fourth 
peptide, known as vasoactive intestinal contracting factor (VIC) or endothelin- 6  
was discovered by genomic cloning in mice (Saida et al., 1989).
ETs are widely distributed in mammals, including humans and non-human 
primates. ETs are similar in structure to VIC and a peptide sarafotoxin (SX) found 
in the venom of a rare snake, Atractaspis engaddensis (Kloog and Sokolovsky, 
1989). In fact several sarafotoxins, SX6 -A, -B, -C, -D and -E all derived from the 
Israeli snake have been characterised (Bdolah et al., 1989; Sokolovsky, 1992). The 
identification of these peptides and the characterisation of their binding sites has
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generated intense and widespread study of the physiology and pathophysiology of 
ETs.
1.7.3 Structural similarities between ET and SXs
As shown in Figure 5 the sequence of the carboxy-terminal tail of ET/SX is 
conserved and the amino-terminal residue is always Cys, which in SX6 A, SX6 B,
ET-1 and ET-2 is followed by Ser and in SX6 C, SX6 D and ET-3 by Thr. The most 
important differences between the various peptides of the ET/SX family are to be
3 11found within the sequence of the inner loop Cys -Cys . All of these peptides 
possess Glu10, and except for SX6 C all have Asp8-Lys9 (Sokolovsky, 1992).
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Figure 5 The primary sequences of endothelin (ET)-l, -2 and -3 showing the 
positions of the disulphide bonds and residues that differ from those of endothelin- 
1 (shaded). The snake venom sarafotoxin 6c is shown for comparison (Webb, 
1991; Huggins et al., 1993).
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1.7.4 Endothelin biosynthesis
The biosynthesis of ETs occurs in a manner much like that of other peptide 
hormones and neurotransmitters. ET isopeptides arise through proteolytic 
processing of isopeptide-specific prohormones. Their precursors, 
preproendothelins-1, -2, -3 are polypeptides consisting of approximately 200 
aminoacids that undergo proteolytic cleavage to form a 38 to 39 amino acid 
peptides designated as big endothelins (Inoue et al., 1989; Rubanyi and Polokoff, 
1994). The mature 21 amino acid peptides ET-1, ET-2 and ET-3 arise through the 
proteolytic processing of the "big" ETs by an endopeptidase called endothelin 
converting enzyme (ECE). The important intermediate steps which are involved in 
the biosynthesis of mature ETs are shown in Figure 6 . The ECE is a membrane- 
bound neutral metalloprotease and has structural homology to neutral 
endopeptidase (Shimada et al., 1994). More recent studies have demonstrated the 
cloning and functional expression of human ECE (Shimada et al., 1995), its amino 
acid sequence has 91 % and 94 % homology to those of rat ECE (Shimada et al., 
1994) and bovine ECE (Ikura et al., 1994), respectively. The conversion of big 
ET-1 to ET-1 by ECE in rat and rabbit lung is blocked by phosphoramidon, a 
metalloproteinase inhibitor (Hisaki et al., 1994b). In rat lung there appear to be 
two isoforms of ECE both of which show preference for big ET-1, or big ET-2 
over big ET-3. One is sensitive to phosphoramidon and exhibits optimal activity at 
pH range 5.3-8.1. Investigations have shown that the ECE activity found in 
endothelial cells which specifically cleaves big ET-1 was inhibited by 
phosphoramidon, whereas other neutral endopeptidase inhibitors such as thiorphan 
or the angiotensin converting enzyme inhibitor, captopril were inactive (Opgenorth 
et al., 1992). In contrast the second ECE is only sensitive to pepstatin-A and 
exhibits ET-converting activity over a pH range of 5.5 - 9.7 (Chiou et al., 1994). 
Recent investigations in guinea pig lung parenchymal strips have also shown the 
presence of two ECEs which selectively convert big ET-1 and big ET-2 but not big 
ET-3. A similar substrate-selective ECE showing preference for big ET-1: big
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ET-2: big ET-3 in a ratio of 40: 2.5: 1 has also been reported in a human 
endothelial cell line (Ahn et al., 1995).
1 17-18 52-53 73-74 90-91 108-109 119-120





Big ET-1 NH, COOH
Endothelin Converting Enzyme ( ECE)
ET-1
Figure 6 Schematic representation of biosynthesis of ET-1 (Yanagisawa et al., 
1988; Rubanyi and Polokoff, 1994).
The physiological importance of the conversion of big ET to ET was demonstrated 
by the observation that ET-1 was 140-fold more potent as a vasoconstrictor 
compared to the precursor peptide (Kimura et al., 1989).The prepro- form of ET-1 
is devoid of any vasoconstrictor action (Cade et al., 1990).
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1.7.5 Endothelin receptors
1.7.5.1 Molecular cloning and characterisation o f receptors
The ET family exerts diverse biological effects which are thought to be mediated 
via the interaction with specific ET membrane receptors. Cloning of two endothelin 
receptors was reported at the end of 1990. One of these clones was isolated from a 
bovine cDNA library and, when expressed in Xenopus oocytes',w&s named as the 
ETa receptor and has a very high selectivity for ET-1, ET-2 and SX6 B over ET-3 
and SX6 C (ET-1 > ET-2 > SX6 B »  ET-3 > SX6 C).The binding affinity of ET-1 
was 100 times greater than that of ET-3 (Arai et al., 1990). The second clone, 
identified in a rat lung cDNA library was named as ETB and had equal affinity for 
ET-1, ET-2 and ET-3 (Sakurai et al., 1990). Human forms of both receptors were 
soon reported and the potency difference of ET-1 relative to ET-3 for the ETA 
receptor was confirmed as approximately 1000-fold (Hosoda et al., 1991). The 
lack of selectivity of the ETs for the human ETB receptors has also been reported 
(Nakamuta et al., 1991; Sakamoto et al., 1991).
Despite the cloning of only two mammalian receptors, functional evidence suggests 
the presence of additional subtypes. The most widely proposed of these is the ETc 
receptor (Kame et a l, 1993) which was cloned from Xenopus laevis in dermal 
melanophores. This is classified as being selective for ET-3 over ET-1 (ET-3 > 
ET-1). This receptor had approximately 50 % amino acid homology with ETA and 
ETb receptors (Kame et al., 1993). In addition to the cloning of ETA ETB and 
ETC receptors a fourth endothelin receptor named as ETax was cloned recently in 
Xenopus heart and shares 74%, 60% and 51% of identities with human ETA ETB 
and Xenopus ETC receptor respectively (Kumar et al., 1994).
In rat lung membranes the existence of two ET receptors (44 kD and 32 kD 
molecular weight) which have different affinities for ETs was proposed. The 44kD 
receptor had a higher affinity for ET-1 or ET-2 compared with ET-3, whereas the 
32 kD receptor exhibited selectivity for ET-3 (Masuda et al., 1989). Cloning of
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ETa receptor subtypes from rat alveolar epithelial cells has recently been reported 
(Markewitz et al., 1995).
ETa receptors have often been found to mediate contractile responses in isolated 
smooth muscle preparations. However, recent studies have shown that a subtype of 
ETa receptor is also present on endothelial cells (Nishimura et al., 1995). In 
addition , the existence of ETA1 and E T ^  receptors is also proposed, where the 
former are BQ-123-sensitive and the latter BQ-123-insensitive (Sudjarwo et al., 
1994; Yoneyama et al., 1995). No selective agonist at ETA receptors has yet been 
reported. Thus, identification of this receptor subtype has to rely on the use of 
selective antagonism of responses to ET-1, either where it is significantly more 
potent than ET-3 or where selective ETB receptor agonists such as SX6 C, BQ- 
3020 or IRL 1620 are inactive (see Bax and Saxena, 1994).
ETb receptors were originally considered as receptors mediating vasorelaxation. 
However, later it was shown that ETB receptors were also involved in smooth 
muscle contraction i.e. rabbit saphenous vein (Moreland et al., 1992). Thus ETB 
receptors have been subdivided into ETBi (located on the endothelium and 
mediating vasorelaxation) and ETB2 (located on the vascular smooth muscle and 
inducing contraction) (Sudjarwo et al., 1993; Warner et al., 1993a; Warner et a l, 
1993b). Sokolovsky et al., (1992) also reported that there appeared to be two 
subtypes of ETB receptors i.e. the 'super high affinity', ETBi- receptors and th e ' 
high affinity', ETB2 receptors. It was suggested that the super high sites showing 
binding affinity in the picomolar range are related to the vasodilator property of 
endothelins whereas the high affinity sites with binding affinity in the nanomolar 
range participate in the vasoconstrictor actions.
1.7.5.2 Receptor antagonists
The best known of the ETA receptor selective antagonists are BQ-123 and BQ- 
153. These were initially isolated from the fermentation broth of Streptomyces 
misakiensis (Ihara et al., 1992). Most recently a sulphonamide derivative BMS-
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182874, has been reported to be a potent orally active selective ETA receptor 
antagonist (Webb et al., 1995).
The non-selective agents PD-142893 and PD-145065 were developed by a rational 
approach starting with ET( 16-21), which is known to interact with ET receptors 
(Doherty et al., 1993). PD-145065 has 4.0 and 15 nM binding affinity (IC50 values) 
for the ETa and (rabbit renal artery vascular smooth muscle cells) and ETB 
receptors (rat cerebellum), respectively. The compound is also an antagonist of 
ET-l-and SX6 C stimulated vasoconstrictor activity, with pA2 values of 6.9 (rabbit 
femoral artery, ETA assay) and 7.1 (rabbit pulmonary artery, ETB assay), (Doherty 
etal., 1993).
The orally active, mixed ETA/ ETB endothelin receptor antagonist bosentan, (Ro 
47-0203), shows 20-50 fold selectivity for ETA receptors. The binding affinities for 
ETBi and ETB2 receptors was 35- and 11- fold lower respectively, than for ETA 
receptors in functional studies with pA2 values of 7.28 , 6.72 and 5.94 respectively, 
against ET-1- induced contractions in de-endothelialized rat aorta (ETA), SX6 C- 
induced relaxation of rabbit mesenteric artery (ETBi) and SX6 C-induced 
contractions of rat trachea (ETB2) (Clozel et al., 1994).
Selective antagonists at ETB receptors which have been described include, IR1038 
(Urade et al., 1992; Karaki, et al., 1993) RES-701-1 (Karaki, et al., 1994) and BQ 
788 (Ishikawa et al., 1994); for review see Huggins et al., 1993; Warner, 1994. 
Figure 7 shows the structures of some endothelin receptors antagonists. The 
anatomical location of the putative endothelin receptor subtypes and their agonists 
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Figure 8 The vascular location of putative subclasses of endothelin receptor 
subtypes and their agonists / antagonists. Modified from Douglas et al., (1994). 
NO is nitric oxide.
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1.7.6 Pharmacological actions
ETs /  SXs produce several actions in vascular and non-vascular smooth muscles 
(for review see Rubanyi and Polokoff, 1994). The contraction of isolated vascular 
smooth muscle in response to ET-1 generally begins at a threshold dose of about 
100 pM (Highsmith et al., 1992). The contractions in vascular smooth muscle are 
mediated via ETA and ETb receptors in animals and humans (Seo et al., 1994;
White et al., 1994). ET-l-induced contractions in isolated human blood vessels 
were blocked with a mixed ETA /  ETB receptor antagonist bosentan (Seo et al.,
1994). In conscious rats ET-1 produces a sustained increase in mean arterial blood 
pressure which is preceded by a transient depressor response (Bird et al., 1993;
Filep et al., 1993; McMurdo et al., 1993). ETs also produce relaxation of pre­
contracted isolated blood vessels (Namiki et al., 1992; Karaki et al., 1993; Shetty 
et al., 1993; Zellers et al., 1994). Among the three ET isopeptides, ET-3 exerted 
the most potent initial depressor response, but the least vasoconstrictor response. 
Warner et al., (1989) have reported that ET-3 is a vasodepressor rather than a 
vasoconstrictor in the isolated perfused rat mesentery acting via the release of 
EDRF. Recent investigations of the distribution of nitric oxide synthase and 
endothelin in coronary and pulmonary arteries of new-born rats have shown that in 
the endothelial cells, nitric oxide synthase and endothelin are co-localised and may 
be substantially involved in the vasomotor control of the cardiac and pulmonary 
circulations (Loesch and Bumstock, 1995). ET-1 is a potent constrictor of smooth 
muscle in isolated trachea and bronchus (see Rubanyi and Polokoff, 1994). ET-1 
also stimulates the proliferation of the vascular smooth muscle cells and is a potent 
stimulus of DNA synthesis and proliferation of pulmonary vascular smooth muscle 
cells (see Barnes, 1994).
ETs also increase vascular permeability in many isolated vascular beds (Filep et al., 
1992; Kurose et al., 1993). In vivo studies have also demonstrated the 
oedemagenic effects of ETs as ET-1 enhanced albumin extravasation in the 
stomach and duodenum of anaesthetised rats (Filep et al., 1993; Filep et al., 1994).
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1.7.7 Physiological and pathophysiological role of ETs
Endothelins are a family of a novel regulatory peptides. Knockout of the ET-1 
gene in mice cause severe craniofacial and thoracic blood vessel malformations 
(Kurihara, 1994) suggesting an important role for ET-1 in normal development. 
However, clinical and experimental evidence has shown that an increase in the 
production of endothelin may be a promoting factor in a number of disease states 
(see review Huggins et al., 1993; Rubanyi and Polokoff, 1994). ETs may play an 
important role in the regulation of pulmonary vascular tone (Barnes and Liu, 1995) 
and are also implicated in pulmonary pathophysiology (Filep, 1993). There is an 
increase in the plasma concentration of ET-1 in patients with pulmonary 
hypertension (Stewart et al., 1991) which could be a reflection of reduced uptake 
of ET-1 from the pulmonary vascular bed resulting from endothelial dysfunction 
(DeNucci et al., 1988) or there may be increased production of ET-1 in the lungs 
of patients with primary pulmonary hypertension. Increased expression of ET-1 
mRNA in an animal model of primary pulmonary hypertension (Stelzner et al., 
1992) and in patients with pulmonary hypertension (Giaid et al., 1993) seems to 
support this hypothesis (Barnes, 1994; Rubanyi and Polokoff, 1994).
Immunoreactive ET-1 has been detected in normal lungs but only in 10 % of 
healthy volunteers. In contrast, ET-1 expression was evident in airway epithelium 
in more than 60 % of asthmatic patients (Springall et al., 1991; Oparil et al.,
1995). ET-1 circulates in normal animals and humans (Ando et al., 1989), and its 
levels have been reported to be increased in several experimental situations i.e. 
acute pulmonary alveolar hypoxia increases lung ET-1 levels in conscious rats 
(Shirakami et al., 1991), and in several clinical conditions i.e. human patients with 
status asthmaticus (Nomura et al., 1989), adult respiratory distress syndrome 
(Druml et al., 1993).
Under physiological conditions the lungs are by far the most important sites of 
endothelin disposal. Recent evidence has shown that in isolated perfused rat lungs
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about 80 % of a bolus injection of [125]jtt-1 was retained by the lungs during 
single passage (Westcott et al., 1990; Fukuroda et al., 1994). In lung disease such 
uptake of ET-1 may be impaired whereas if lung ET release remained constant or 
increased, the pulmonary circulation would be exposed to elevated ET 
concentrations which would adversely affect the microcirculation.
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1.8 Objectives:
I. To develop a rat isolated perfused lung model which would allow simultaneous 
monitoring of pulmonary perfusion pressure, lung weight and pulmonary inflation 
pressure.
n. To validate the model by using selective agonists for the measured parameters.
III. To determine whether increases in lung weight are associated with increased 
filtration and /  or permeability changes.
IV. To characterise and localise the actions of ETs and SX6 C in the perfused lungs.






Male Wistar rats (300-350 g) were supplied by the University of Bath Animal House.
2.2 Pru2s and Chemicals
Drugs and Chemicals were obtained from the following sources:
British Drug Houses (BDH), Poole:
Atropine sulphate 
Evans blue dye







Sigma Chemical Company, Poole, Dorset:















Rhone Merieux Ltd, Harlow, Essex
Pentobarbitone hydrochloride (Sagatal)
General laboratory grade chemicals were purchased from British Drug Houses (BDH), 
Poole and Sigma Chemical Company, Poole.
The following were gifts:
BQ123 (cyclo[ D-Asp-L-Pro-D-Val-L-Leu-D-Trp]) was supplied by Dr. K. Clark, Glaxo 
Group Research (Ware, Herts)
Bosentan (Ro 47-0203; 4-tert-Butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)- 
2,2'-bipyrimidin-4-yl]-benzenesulfonamide sodium salt) was provided by Hoffmann-La 
Roche Ltd (Basel, Switzerland).
PD145065; Ac-(D-2-(10, 11 -dihydro- 5H - dibenzo [a, d] cyclohepten-5-yl) Gly-LLeu- 
LAsp-Llle-Llle-LTrp. Na (1 : 2) was a kind gift from Parke-Davis Pharmaceutical 
Research, Ann Arbor, Michigan (USA).
2.2.1 Physiological salt solutions
Krebs' solution was prepared with the following composition (mM): potassium chloride 
(4.7); potassium dihydrogen phosphate (1.2); calcium chloride (1.25); magnesium 
sulphate (1.2); sodium chloride (118); sodium bicarbonate (25); glucose (11.1).
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2.2.2 Heparin solution: Heparin was dissolved in normal saline and stored in ampoules 
(1000 i.u. m l'l) a t4  °C.
2.2.3 Indomethacin solution: prepared just before use by dissolving in an equimolar 
amount of sodium carbonate in normal saline.
2.2.4 U46619 solution: U46619 was dissolved in 95 % ethanol, dilutions were made in 
0.9 % normal saline (10"3 M) this stock was stored at -80 °C.
Stock solutions of all drugs were prepared in normal saline and aliquots were stored at - 
20 °C.
2.3 Isolated ventilated perfused lung preparation
Male Wistar rats were anaesthetized with an intraperitoneal injection of Sagatal (60 mg 
kg 'l body weight). Heparin (500 i.u.) was injected via the tail vein to prevent 
intravascular clotting and 5 min later the chest wall was opened by a midline sternotomy. 
The thymus and fatty tissue were carefully excised and a suture was placed around the 
pulmonary artery and secured with a loose knot. At this time the perfusion circuit was 
checked to ensure that it was filled with perfusate and that no air bubbles remained in 
the tubing. A small cut was made in the right ventricular wall and the pulmonary artery 
cannulated with a stainless steel cannula (external diameter = 1.5mm, internal diameter = 
1 mm) via the right ventricle. The cannula was secured by tightening the suture. The left 
atrium was cut and the major part of the ventricles removed to allow free efflux of the 
perfusate. The lungs were flushed with Krebs' solution via the pulmonary artery cannula.
Following pulmonary artery cannulation, a medial incision was made in the ventral 
surface of the neck and a section of the trachea exposed by blunt dissection. The trachea 
was partially transected, and a metallic cannula inserted and secured with a cotton suture. 
Thereafter, the trachea and the lungs were isolated from the chest cavity and immediately 
transferred into a warming jacket maintained at 37°C. Lungs were perfused via the 
pulmonary artery at constant flow of 5ml min~l with Krebs' solution (gassed with 95% 
O2 & 5% CO2) using a roller pump. Pulmonary artery perfusion pressure (PPP) was 
recorded via a side arm of the inflow perfusion tubing connected to a pressure 
transducer. The tracheal cannula was attached to a ventilator and the lungs were 
ventilated with room air, stroke volume (1  ml) using 28 strokes min“l (no positive end 
expiratory pressure). A side arm was attached to a pressure transducer for recording the 
pulmonary inflation pressure (PIP). Lungs were attached to an isometric transducer by a 
wire from the tracheal cannula for recording changes in lung weight (LW). The 
experimental set up is shown in Figure 9. All parameters were recorded on a 
multichannel recorder (Grass model 7D polygraph). Lungs were allowed to stabilize for 
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Figure 9 Diagram of the rat isolated perfused lung. PPP- pulmonary perfusion pressure, 
PIP- pulmonary inflation pressure.
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2.3.1 Alteration o f venous outflow pressure (VOP)
In a different series of experiments, a plastic cannula (external diameter = 2mm, internal 
diameter = 1.5mm) was also introduced into the left atrium via the left ventricle. This 
cannula was attached to a constant-head reservoir which was connected to a pressure 
transducer and VOP was monitored along with PPP, lung weight and PIP (Figure 10).
By raising the level of the reservoir VOP could be manipulated over the range 5-25 
mmHg. These increases in pressure were maintained for 1 min before returning outflow 





Room air; 28 strokes m in1 PIP
Krebs solution; 5 ml m in1  PPP
Warming jacket
Figure 10 Manipulation of venous outflow pressure (VOP) in the rat isolated perfused 
lung. PPP- pulmonary perfusion pressure, PIP- pulmonary inflation pressure.
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2.3.2 Retrograde perfusion
In another set of experiments a cannula was introduced into the left atrium via the left 
ventricle and lungs were perfused via the pulmonary vein and pulmonary venous pressure 
monitored together with LW and PIP. Drugs were injected as bolus doses (10-100 pi) 
via the pulmonary venous cannula.
2.4 Bioassay methods
For bioassay, the effluent from the lungs was superfused over the assay tissue in the 
cascade below the lung chamber. The assay tissues were (a) rat fundic stomach strips, (b) 
rat ascending colon (Vane, 1969). The bioassay tissue preparations were allowed to 
equilibrate for 30-45 min before the lungs were included in the circuit. The amount of 
substances activated or inactivated by the lungs was determined by comparing the 
contractions of assay tissues to bolus injections of agents made directly into the fluid 
superfusing the assay tissues with responses to injections of agents made into the 
pulmonary arterial cannula. When used, inhibitors were added into the perfusate 30 min 
before giving the agonist injections.
2.5 Determination of albumin-bound dye extravasation
Evans blue dye was added to a 10 % (w v-*) solution of bovine serum albumin (BSA) in 
saline to give a final concentration of 1 mg ml"l. The mixture was dialysed overnight in 
Visking tubing (22/32) against an excess of distilled water. Aliquots of the solution were 
infused into the pulmonary artery (0.1 ml min"*) for a 5 min period. Drugs were injected 
one min after the start of dye infusion. In separate experiments VOP was raised to 20 
mmHg for 1 min during dye infusion. Lungs were perfused for a further 3 min to remove 
unbound dye from the vasculature. Lungs were removed and after removal of cardiac 
tissue and trachea the lungs were oven dried (50-60 °C) overnight and dry weight noted. 
Lungs were then digested with formamide (2-4 ml /  0.3 g dry tissue weight) at 40 °C in a 
water bath for 20 h and the contents were centrifuged (Eppendorf centrifuge 5414) at 
9880g for 30 min. The absorbance of standard concentrations of Evans blue (0.25- 20
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pg ml‘ l) or lung extracts were read at 622 nm in a spectrophotometer (Pye Unicam) The 
concentration of dye in lung extracts was calculated by reference to a standard curve 
range of Evans blue dye. Using this value fluid accumulation in the lung could be 
calculated by reference to the concentration of dye in the fluid perfusing the lung.
In a different protocol albumin-bound Evans blue dye solution was infused into the 
pulmonary artery (0.1 ml min-1) for 5 min, 1 min after agonist injection. Lungs were 
perfused for a further 1 0  min to remove unbound dye from the vasculature and retained 
dye was extracted as explained above.
2.6 Effects of inhibitors and receptor antagonists
2.6.1 Inhibitors
In a series of experiments effects of the inhibitors of: cyclooxygenase (indomethacin 
lOpM), angiotensin converting enzyme (captopril 10 pM), neutral endopeptidase 
(phosphoramidonl pM), nitric oxide synthase (nitro-L-arginine 100 pM)were 
investigated. Each inhibitor was studied in individual experiments and was added into the 
perfusate 30 min before giving the agonist injections and was present for the remainder 
of the experiment.
In some experiments to differentiate the increases in PPP from changes in lung weight, 
the vasodilator papaverine (20 pM) was added 30 min before giving the bolus injections 
of agonists.
2.6.2 Receptor antagonists
Antagonists were perfused 30 min before giving the bolus injections of the appropriate 
agonists in to the pulmonary artery. Dose-response curves for each agonist were 
completed in the presence of the antagonist.
2.7 Elevation of basal PPP to investigate the pulmonary vasodilator actions o f  
agonists
In a series of experiments basal PPP was elevated using the thromboxane mimetic 
U46619. This was infused with an infusion pump (Harvard Apparatus 22) into the 
pulmonary artery. Infusion of U46619 was started after 20 min of an initial stabilisation 
period and a further 5-10 min were given to stablise the perfusion pressure after which 
bolus injections of agonists were given into the pulmonary artery.
2.8 Statistical analyses
Increases in PPP, PIP and lung weight induced by bolus injections of phenylephrine, 
carbachol, bradykinin, endothelins and sarafotoxin 6 c are expressed relative to the basal 
values prior to the addition of each dose. Pulmonary vasodilator responses to ETs, 
sarafotoxin 6 c and sodium nitroprusside are expressed as % decreases with respect to the 
raised PPP induced by U46619 infusion. When lung weight measurement was needed for 
comparative purposes, weight gain was calculated 7 min after giving the maximum dose 
of agonist. Data were expressed as mean ± standard error of the mean (SEM). Analysis 
of variance (ANOVA) followed by Dunnett's (Dunnett, 1964) or Student's (unpaired) t- 
tests were used to test the level of significance as appropriate. Probability values of P< 




3.1 Effects o f perfusion time on lung weight
To determine the effects of perfusion time on lung integrity, an initial series of 
experiments monitored lung weight after differing periods of perfusion at 5 ml min“l 
(Figure 11). Initial lung weight (2.8 ± 0.2 g ; mean ± SEM, n =5) had increased by 0.22 
± 0.1 lg  after 2h (NS); 0.7 ± 0.2g after 2.5h of perfusion ; by 1.15 ± 0.28g after 3h and
2.9 ± 0.98g after 4h perfusion. These later changes were significant when compared 
with initial lung weight (P< 0.05, ANOVA). When perfusion rate was increased to 10 ml 
min1 in 2  experiments lung weight was increased markedly after one hour which was too 
short to carry out the experiments. Therefore in all subsequent experiments lungs were 
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Figure 11 Effect of perfusion time on lung weight. Each point represents mean ± SEM, 
n= 5. *p< 0.05; 1 way ANOVA.
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3.2 Differential pulmonary vascular and bronchial actions o f vasoactive substances
The effects of three agonists, phenylephrine ( PHE ), carbachol ( CCh ) and bradykinin 
(BK) on three lung parameters (PPP, lung weight & PIP ) are shown in Figure 12. As 
shown PHE (3.12-50 nmol) dose-dependently increased PPP. However PHE was 
without effect on lung weight or PIP. CCh (1.5-48 nmol) selectively increased PIP 
without affecting PPP or lung weight. BK (6.25-200 nmol) dose-dependently increased 
PPP, PIP and lung weight. Low doses of BK (12.5 - 50 nmol) produced reversible 
increases in lung weight and PIP, but higher doses of BK (100 - 200 nmol) produced 
increases in lung weight and PIP which were only partially reversible.
Accumulated results for the actions of all three substances on the three monitored 
parameters are shown in Figure 13. From Figurel3a, it can be seen that PHE was the 
most potent vasoconstrictor agent having an ED50 of 4.0 ± 0.7 nmol (n =5). BK had a 
lower potency (ED50 22 ± 3.0 nmol, n = 8  ) while CCh did not increase PPP in any 
experiment (n =7).
Figure 13b illustrates that CCh was the most potent bronchoconstrictor with an ED50 of 
4.25 ± 0.4 nmol (n =7). BK was less potent (ED50 of 35.6 ± 3.6 nmol, n =8 ) while PHE 
was devoid of bronchoconstrictor activity.
Figure 13c illustrates that BK was the only substance which affected lung weight. 
Increases in weight were linear over the dose range studied. Such a curve disguises the 
fact that BK caused a reversible increase in lung weight at low doses (12.5-50 nmol) as 
illustrated in Figure 12c. However at higher doses (100-200 nm ol) the gain in lung 
weight was sustained.
Figure 12 The differential actions in the perfused lung of (a) phenylephrine, (b) 
carbachol and (c) BK on lung weight (LW), pulmonary perfusion pressure (PPP) and 
pulmonary inflation pressure (PIP). Each trace represents one of 5-8 such experiments. 
Note: different scale for LW parameter in BK.
(l°rau) oor os g.zx 
,OOT .
I t i l l  f
Qomn) sp u  £
I PZ
I ♦ l i l t
1






I ! | I : i I :! • 11 •:'! I i ;
!ii!
(q)







Figure 13 Actions on (a) pulmonary arterial perfusion pressure (PPP), (b) pulmonary 
inflation pressure (PIP) and (c) lung weight (LW) of phenylephrine (PHE) ( O  ), carbachol 
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3.3 Effects o f inhibitors and receptor antagonists
3.3.1 Indomethacin
Effects of the cyclooxygenase enzyme inhibitor indomethacin were examined on the 
pulmonary vascular and bronchial actions of PHE, CCh and BK. Inclusion of indomethacin 
(10 pM) in the perfusate did not influence any of the basal parameters. There was a small 
but significant (p < 0.05) increase in the maximal PPP response (from 10.1 ± 0.56 mmHg, n 
= 8  to 12.9 ± 0.9 mmHg, n =6 ) following 200 nmol BK but not to PHE. Furthermore ED50 
values for BK (ED50 31.2 ± 2.0 nmol, n =6 ) and PHE (ED5 0 4 . 5  ± 0.9 nmol, n =4) were not 
significantly different to controls. Indomethacin had no effect on the bronchoconstrictor 
action of BK (ED5 0 47.1 ± 4.6 nmol, n =6 ) or carbachol (ED50 3.0 ± 0.13 nmol, n =4) 
compared to control values quoted above.
3.3.2 Captopril
Effects of the angiotensin converting enzyme inhibitor captopril on BK- mediated PPP, lung 
weight and PIP increases were investigated.
Perfusion of captopril (10 pM), a concentration which completely attenuated the pulmonary 
vascular and bronchial responses to angiotensin-I (62.5-1000 pmol), significantly potentiated 
the effects of BK on PPP (control ED50 value reduced from 22 ± 3 nmol, n = 8  to 0.34 ± 
0.04 nmol, n =5 p< 0.001), lung weight and PIP (control ED50 value reduced from 35.6 ± 
3.6 nmol, n = 8  to 0.8 ± 0.2 nmol, p< 0.001 , n =5).
In addition the superfusion bioassay method was used to study the role of angiotensin 
converting enzyme in the pulmonary circulation to inactivate BK. Experiments have shown
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that in the absence of angiotensin converting enzyme inhibitor captopril, angiotensin-I when 
given into the pulmonary arterial cannula produced large contractions of the rat colon, 
whereas captopril (10 pM) completely attenuated angiotensin-I induced contractions of rat 
colon. Furthermore BK given direct over the assay tissue rat stomach fundal strip, induced 
large contractions. However in the absence of captopril, when BK was given via the 
pulmonary arterial cannula its responses were reduced, whereas in presence of captopril (10 
pM) BK induced responses of the stomach strip were markedly potentiated (data not 
shown).
3.3.4 Receptor antagonists
Effects of receptor antagonists on pulmonary vascular and bronchial actions of agonists 
were studied. In four experiments perfusion of the selective kinin B2 receptor antagonist [D- 
Arg°,Hyp3,Thi5’8, D-Phe7]-bradykinin (500 nM) markedly attenuated the PPP, PIP and lung 
weight responses to BK (6.25-200 nmol). However it had no effect on the vasoconstrictor 
responses to PHE or bronchoconstrictor responses to CCh (data not shown).
In a different set of experiments the vasoconstrictor effects of PHE (3.12-50 nmol, n=4) 
were selectively antagonised in the presence of prazosin (lpM) and the bronchoconstrictor 
effects of carbachol (1.5-48 nmol, n=4) were also completely blocked with atropine (100 
nM) without effecting BK responses (data not shown).
3.3.5 Papaverine
Effects of the vasodilator papaverine on BK-mediated responses were studied to see if lung 
weight changes produced by BK are secondary to increases in vascular resistance. 
Papaverine (20 pM) had no effect on the basal PPP, lung weight and PIP (n =3). However 
perfusion of papaverine markedly attenuated BK- mediated(6.25-200 nmol) increases in
PPP, lung weight and PIP. Accumulated results from 3 different experiments have shown 
that the maximum increase in PPP (10 ± 0.6 mmHg, n =8) in response to 200 nmol of BK in 
control lungs was significantly attenuated to 5.3 ±1.5 mmHg, n =3; p< 0.01) in the presence 
of papaverine. In control lungs 200 nmol of BK produced 0.41 ± 0.04 g increase in lung 
weight which was only partially reversible. However, in the presence of papaverine (20 pM) 
the increase in lung weight produced with 200 nmol of BK was reversible and markedly 
reduced to 0.12 ± 0.06 g, n =3 (p<0.01). BK- mediated maximum PIP increase in the 
absence of papaverine was 2.6 ± 0.4 mmHg, n=8. However in the presence of papaverine 
maximum PIP was reduced to only 1 ± 0.2 mmHg, n=3 (p< 0.001).
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3.4 Effects of raised VOP
To investigate if increases in VOP could account for lung weight changes associated with 
BK, VOP was increased in increments of 5 mmHg. As illustrated in Figure 14 such 
increases produced corresponding increases in PPP. Increases in VOP from 5-15 mmHg 
also produced reversible increases in lung weight and PIP. However rises from 20-25 mmHg 
in VOP produced gains in lung weight and PIP which were only partially reversible. 
Furthermore when VOP was increased to 25 mmHg the increase in lung weight was 
accompanied by the appearance of fluid in the tracheal cannula.
I-------  —
4 min
Figure 14 The effects of increasing venous outflow pressure (VOP) for 1 min periods on 
pulmonary perfusion pressure (PPP), lung weight (LW) and pulmonary inflation pressure 
(PIP). This figure represents one of 6 similar experiments.
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3.5 Determination of albumin-bound dye extravasation
To investigate whether both reversible and irreversible changes in lung weight induced by 
BK or VOP were due to changes in vascular permeability, experiments utilizing Evans blue 
dye linked to BSA were carried out. The results are shown in Figure 15. Control lungs 
perfused with dye did not retain any detectable activity. Similarly lungs which received a 
low dose of BK (25 nmol) did not retain dye despite registering a small reversible increase 
in lung weight (Figure 12c). At a higher dose of 200 nmol (which caused a large sustained 
increase in lung weight) marked retention of dye by the lung was noted (23.3 ± 0.4 ng mg'1 
of dry tissue, n =6). Back-calculation of fluid retention from retained dye indicated that 200 
nmol of BK caused an accumulation of 0.32 ± 0.05 ml (n =6) of fluid. Assuming a specific 
gravity of 1 for this fluid a comparison of this calculated weight gain with weight gain 
recorded experimentally (0.38 ± 0.05g, n =6) illustrates that the values are in good 
agreement
In a different set of experiments a rise in VOP of 20 mmHg increased PPP by 11.1 ± 0.9 
mmHg (n = 6), which was associated with an irreversible lung weight increase of 0.61 ±
0.21 g, n =3). There was a large concomitant accumulation of albumin-bound dye (30.5 ±
8.4 ng mg-l of dry tissue, n=3, Figure 15). In comparison 200 nmol of BK caused a similar 
increase in PPP of 10 ± 0.6 mmHg (n=6) which was associated with an irreversible weight 
increase of 0.38 ± 0.05 g.
Furthermore using retrograde perfusion 200 nmol of BK produced an increase in PPP (9.75 
± 0.5 mmHg, n=4) similar to that produced by BK when using orthograde perfusion (10 ± 
0.6 mmHg, n=6). However with retrograde perfusion 200 nmol of BK produced 
significantly less increase in lung weight (0.15 ± 0.02 g, p< 0.05) and dye retention ( 12 ±
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Figure 15 Effects of bradykinin (BK) on vascular permeability in the perfused lung. BK 25 
nmol (hatched column) did not cause dye retention when compared to control lungs (open 
column). BK 200 nmol (cross hatched column) orthogradely and manipulation of (VOP) 
(solid column) both produced significant extravasation and dye retention (*p<0.05; 
**p<0.01 (1 way ANOVA). In retrogradely perfused lungs BK (200 nmol) produced 
significantly less dye retention compared with orthogradely perfused lungs (p< 0.05; 
Students t-test). Results are mean ± SEM, n= 4-6 experiments.
71
3.6 Vascular and bronchial actions of endothelins ( ETs) and Sarafotoxin 6c (SX6C)
3.6.1 Effects on pulmonary perfusion pressure (PPP)
The effects of endothelin-1 (ET-1), endothelin-3 (ET-3) and sarafotoxin 6 c (SX6 C) on PPP 
in 3 different experiments are illustrated in Figure 16. As shown over the dose range used 
(50-800 pmol) all three agonists dose-dependendy increased PPP (basal PPP was 6.7 ±0.5 
mmHg, n =27). The increases in PPP produced by ET-1 (50 - 200 pmol) were not 
completely reversible at low doses, whereas higher doses (400-800 pmol) produced 
reversible increases in PPP. In contrast ET-3 and SX6 C produced reversible increases in 
PPP at all doses. The accumulated results for ETs (ET-1, ET-2 & ET-3) and SX6 C on PPP 
are shown in Figure 17. From Figure 17a, it can be seen that over the dose range used the 
order of potency of the ETs was ET-1 > ET-2 > ET-3. SX6 C was of similar potency to ET- 
1 with ED50 values of 165 ± 19 pmol, n = 6  and 130 ± 17 pmol respectively (n = 10).
3.6.2 Effects on lung weight
Figure 16 shows that ET-1 produced a very steep and irreversible increases in lung weight 
(basal lung weight 2.8 ± 0.06 g, n =27) which was associated with the appearance of fluid in 
the tracheal cannula. ET-3 produced an increase in lung weight at higher doses (800 pmol) 
when compared to ET-1. Interestingly SX6 C (50-800 pmol) produced very little increase in 
lung weight. Figure 17b shows the accumulated results for the effects of ETs and SX6 C on 
lung weight. The order of potency of the ETs was ET-1 > ET-2 > ET-3. In contrast, SX6 C 
which was equipotent with ET-1 on PPP caused no significant change in lung weight over 
the dose range used.
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3.63 Effects on pulmonary inflation pressure (PIP)
As shown in Figure 16 ETs (ET-1 and ET-3) were equipotent on PIP (basal PIP 5.0 ± 0.01 
mmHg, n=27) but SX6 C was the most potent agent. Figure 17c illustrates SX6 C was the 
most potent bronchoconstrictor agent (ED50 80 ± 6  pmol, n=6 ) when compared with ET-1, 
ET-2 and ET-3. The three ETs were equipotent on PIP. The ED50 values for the ETs (ET-1 
216 ± 2 pmol, n= 10; ET-2 277 ± 7 pmol, n=4 and ET-3 268 ± 4 pmol, n= 8 ). In addition 
the slope of the PIP response to SX6 C was significantly steeper than that for any of the ETs 
(p< 0 .0 0 1 ).
Figure 16 Experimental traces showing the actions of ET-1, ET-3 and SX6C on 
pulmonary perfusion pressure (PPP), lung weight (LW) and pulmonary inflation pressure 
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Figure 17 Effects of ETs and SX6 C on (a) pulmonary perfusion pressure (PPP), (b) lung 
weight and (c) pulmonary inflation pressure (PIP). ET-1 ( O ), ET-2 ( •  ), ET-3 ( A ) and 
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3.7 Effects of inhibitors and receptor antagonists on responses to ETs and SX6C
3.7.1 Indomethacin
The cyclooxygenase inhibitor indomethacin (lOpM) had no effect on basal PPP (5.4 ± 0.43 
mmHg)j PIP (5 ± 0.3 mmHg) or lung weight (2.8 ±0.1 g) (n= 14), and did not affect the 
actions of ET-1 on PPP (ED50 value of 132 ± 14 pmol was not different to control ED50 of 
130 ± 17 pmol, n= 10), PIP (ED50 of 200 ± 2 pmol compared to control EDsoof 216 ± 2 
pmol, n= 10) or lung weight (maximum increase produced by 400 pmol ET-1 in the 
presence and absence of indomethacin was 4 ± 0.9 g and 4.5 ± 0.8 g, n= 10 respectively) 
Figure 18.
SX6 C-mediated responses were also unaffected by indomethacin (lOpM) Figure 18a. PPP 
ED50 values for SX6 C in the presence and absence of indomethacin were 142 ±11 pmol (n= 
4) and 165 ± 19 pmol (n= 6 ) respectively, while the corresponding PIP ED50 values in the 
presence and absence of indomethacin were 81 ± 8  pmol (n= 4) and 80 ± 6  pmol (n= 6 ). 
SX6 C had no significant effect on lung weight with or without indomethacin.
Figure 18 Effects on ET-1 and SX6 C on (a) pulmonary perfusion pressure (PPP) (b) lung 
weight and (c) pulmonary inflation pressure (PIP) in the presence (filled symbols) and 
absence (open symbols) of indomethacin (10 pM). ET-1 (O, • )  and SX6 C (A, A). Each 
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3.7.2 Phosphoramidon
The effect of the neutral endopeptidase inhibitor phosphoramidon was studied, to 
determine if breakdown of ETs by neutral endopeptidases reduced their 
bronchoconstrictor potencies. Phosphoramidon (1 pM) had no effect on the basal PPP ( 6  
± 0.5 mmHg), lung weight (2.7 ± 0.06 g) and PIP (4.8 ± 0.17 mmHg) (n= 9). However 
perfusion of phosphoramidon (1 pM) significantly potentiated the effect of ET-3 (800 
pmol) on PPP ( 800 pmol increase PPP in control 9.75 ± 0.57 mmHg, n= 8  was 
potentiated to 13 ± 0.4 mmHg, n= 6 ; p< 0.01). Whereas it had no effect on PPP 
responses to lower doses of ET-3 (50- 400 pmol) Figure 19a.
Lung weight increases to ET-3 were significantly potentiated in the presence of 
phosphoramidon (1 pM). ET-3 (800 pmol) lung weight increase in control lungs was 1.6 
± 0.4 g, n=8 , this was potentiated to 4.56 ± 0.74 g, n= 6  (P< 0.001) in the presence of 
phosphoramidon (Figure 19b).
Figure 19c illustrates that phosphoramidon (1 pM) had no marked effect on the PIP 
responses to ET-3, the ED50 value 264 ± 45 pmol( n=6 ) was not different to the control 
value quoted above.
The selectivity of action of phosphoramidon is illustrated by its lack of effects on SX6 C 
mediated responses. Figure 19 shows that phosphoramidon (1 pM) had no effect on the 
PPP (ED5 0 168 ± 17 pmol, n=3) lung weight and PIP ( ED50 76 ± 8  pmol, n=3) 
responses to SX6 C when compared to control responses.
Figure 19 Effects of ET-3 and SX6 C on (a) pulmonary perfusion pressure (PPP) (b) 
lung weight and (c) pulmonary inflation pressure (PIP) in the presence (filled symbols) 
absence (open symbols) of phosphoramidon ( lpM). ET-3 (O, • )  and SX6 C (A, A) 
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Pulmonary actions of ET-1 were investigated in the presence of the vasodilator 
papaverine, to see if increases in vascular resistance accounted for lung weight changes. 
Papaverine (20 pM) had no effect on basal PPP (6.8 ± 0.5 mmHg), lung weight (2.9 ± 
0.06 g) and PEP (5 ± 0.12 mmHg). However, it abolished ( P< 0.001, n=4-7) the changes 
in PPP, lung weight and PIP in response to ET-1 (50- 800 pmol). Results are shown in 
Figure 20.
Figure 20 ET-l-induced increases in (a) pulmonary perfusion pressure (PPP), (b) lung 
weight and (c) pulmonary inflation pressure (PIP) in the absence (O) and presence (#)of 
papaverine (20 pM). Each point represents mean ± SEM, n= 4 - 7 experiments. * p< 
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3.8 Endothelin receptor antagonists
3.8.1 Selective ETA receptor antagonist 
BQ123
BQ123 a selective ETA receptor antagonist (Ihara et al., 1992) in the concentration range 
1 pM to 10 pM had no effect on basal PPP (6.3 ± 0.4 mmHg), PIP (4.7 ± 0.15 mmHg) 
and lung weight (2.6 ± 0.08 g) (n= 18). Figures 21 and 22 illustrate the effects of BQ123 
on ET-1 mediated changes in PPP, lung weight and PIP. The effects of BQ123 on ET-1 
mediated increases in PPP are shown in Figure 22a. In the presence of BQ123 (lpM) 
PPP responses to low doses of ET-1 (50-100 pmol) were significantly inhibited (p< 0.05) 
whereas the response to the highest dose of ET-1 (800 pmol) was significantly 
augmented (ET-1 800 pmol PPP increase in control 10.4 ±1.6 mmHg, n= 4 was 
potentiated to 21 ± 3.6 mmHg, n= 5; p< 0.01). However, perfusion of 2pM BQ123 
significantly attenuated the effects of ET-1 on PPP and the dose-response curve showed 
a rightward parallel shift with a significant increase in ED50 value (control ED5 0 130 ± 17 
pmol (n= 10) to 311 ± 3 pmol (n = 4; p< 0.01) in the presence of BQ123. However, 
BQ123 at 2 pM had no effect on the maximal increase in PPP induced by ET-1. 
Furthermore use of the higher concentration of BQ123 (10 pM) markedly attenuated 
PPP responses to ET-1 (50- 800 pmol). The increase in PPP was reduced to 5.3 ±1.3 
mmHg, n= 3 (p < 0.01) in the presence of 10 pM BQ123, when compared to the control 
value quoted above. Interestingly, in the presence of BQ123, ET-1 caused transient 
increases in PPP (Figure 21).
Figure 22b illustrates, that BQ123 produced a concentration-dependent reduction of the 
lung weight increase in response to ET-1 (50- 800 pmol). The maximum increase in lung 
weight produced in response to 800 pmol ET-1 (8.1 ± 0.1 g, n =4) was reduced in the 
presence of 1 pM BQ123 to 4.5 ± 0.8 g, n = 4 (p < 0.001). BQ123 (2 pM and 10 pM)
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further attenuated the ET-1 (800 pmol)-induced increase in lung weight to 0.8 ± 0.2 g, 
n = 4 and 0.4 ± 0 g, n =3 (p< 0.001) respectively.
Interestingly, BQ123 (1-10 pM) augmented the effects of ET-1 on PIP (Figure 22c). The 
control ED50 (216 ± 2 pmol, n =10) for ET-1 was reduced to 78 ± 12.3 pmol, n =5 (p< 
0.001) in the presence of 1 pM BQ123, 107 ± 17 pmol, n= 4 (p<0.05) in the presence of 
2 pM BQ123, and 87 ± 20 pmol, n =3 (p< 0.001) in the presence of 10 pM BQ123. In 
addition the dose-response curves to ET-1 over the dose range 50-200 pmol in the 
presence of BQ123 were significantly steeper than the controls (p<0.001).
The selectivity of BQ123 for ETA receptors was studied with its effects on SX6 C - 
mediated responses. BQ123 (2pM) did not affect the PPP response to SX6 C; control 
ED50 was 165 ± 19 pmol (n = 6 ) and in the presence of BQ123 was 184 ± 20 pmol (n = 
3). Use of the higher concentration of BQ123 (10 pM) also had no effect on PPP 
responses to SX6 C (50- 400 pmol). Similarly, SX6 C-induced changes in PIP were not 
altered by the higher concentration of BQ123; control ED50 was 80 ± 6  pmol (n = 6 ) and 
in presence of 2 pM and 10 pM BQ123 was 6 8  ± 2 pmol and 71 ± 4 pmol (n = 3) 
respectively. These results are shown in Figure 23.
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Figure 21 Experimental trace showing the effects of ET-1 on PPP, lung weight and PIP 
in the presence of BQ123 (10 pM). This represents one of 3 such experiments.
Figure 22 ET-l-induced increases in (a) pulmonary perfusion pressure (PPP), (b) lung 
weight and (c) pulmonary inflation pressure (PIP) in the absence (open circles) or 
presence of BQ123 (1 pM) (filled circles), (2 pM) (open triangles) and (10 pM) (filled 
triangles). Each point represents mean ± SEM, n= 4-10 experiments. * p< 0.05; ** p< 
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Figure 23 SX6C-induced increases in (a) pulmonary perfusion pressure (PPP), (b) lung 
weight and (c) pulmonary inflation pressure (PIP) in the absence (open circles) or 
presence of BQ123 (2 pM) (filled circles), (10 pM) (open triangles). Each point 
represents mean ± SEM, n = 3 - 6 experiments.
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3.8.2 Mixed (ETA IETB) endothelin receptor antagonists
3.8.2.1 Bosentan (Ro 47-0203)
Bosentan (5 pM), a non-peptide mixed endothelin receptor antagonist (Clozel et al., 
1994), had no effect on the basal PPP (5 ± 1 mmHg), PIP (5  ± 0.2 mmHg) and lung 
weight (2.7 ± 0.14 g) (n= 8). However, it reduced (p< 0.001, n=4) the ET-1 (50-800 
pmol)-induced PPP and lung weight responses as shown in Figure 24a and 24b, 
respectively. In contrast, bosentan did not affect ET-1-induced PIP responses (control 
ED50 242 ± 34 pmol, n=7; presence of bosentan ED50 291 ± 90, n=4) (Figure 24c). 
Responses to SX6C on PPP, PIP and lung weight were attenuated (p< 0.001, n=4) by 
bosentan (Figure 24).
The selectivity of bosentan for endothelin receptors was illustrated by its lack of effects 
on the PHE mediated responses. In the presence of 5 pM bosentan PPP responses to 
PHE were not altered (control ED50 4 ± 0.7, n=5; ED50 in the presence of bosentan 3 ± 
0.2 nmol, n=3).
Figure 24 Effects of ET-1 and SX6C on (a) pulmonary perfusion pressure (PPP) (b) 
lung weight and (c) pulmonary inflation pressure (PIP) in the absence (open symbols) or 
presence of bosentan (5 pM) (filled symbols). ET-1 (O, • )  and SX6C (A, A )  Each 
point represents mean ± SEM, n= 4-13 experiments. *** p< 0.001: significantly different 
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3.82.2 PD145065
PD145065 (0.3-1 pM) another mixed endothelin ETA / ETB receptor antagonist 
(Doherty et al., 1993) had no effect on the basal PPP (5.7 ± 0.5 mmHg), lung weight 
(2.8 ± 0.13 g) and PIP (5 ± 0.2 mmHg) (n= 13). However, 0.3 pM PD145065 
attenuated (p< 0.001) the PPP responses to ET-1 (50 - 400 pmol). Perfusion of 1 pM of 
PD 145065 further attenuated (P< 0.001, n=3) the PPP responses to ET-1 (50-800 pmol) 
(Figure 25a).
Figure 25b illustrates that both concentrations of PD 145065 (0.3 pM and 1 pM) 
abolished (p< 0.001) the increases in lung weight produced by ET-1 (50-800 pmol).
Interestingly, PD145065 (0.3 - 1 pM) potentiated the PIP responses to ET-1 (Figure 
25c). ED50 values in the presence of 0.3 pM (134 ± 33 pmol, n=4) and 1 pM (112 ± 2.5 
pmol, n=3; p< 0.01) were significantly reduced when compared with control value.
PD 145065 (0.3 - 1 pM) attenuated (p< 0.001, n=3) the PPP, lung weight and PIP 
responses to SX6 C (50- 800 pmol) Figure 26.
The selectivity of PD 145065 for endothelin receptors,was studied by its effects on the 
vasoconstrictor responses to PHE. Use of 1 pM PD 145065 had no significant effect on 
PPP responses to PHE (control ED50 4 ± 0.7 nmol, n= 5; ED50 in the presence of 
PD 145065, 3 ± 1 nmol, n=3).
Figure 25 ET-1-induced increases in (a) pulmonary perfusion pressure (PPP) (b) lung 
weight and (c) pulmonary inflation pressure (PIP) in the absence (open circles) or in the 
presence of PD 1450656 (0.3 pM, filled circles), (1 pM) (open triangles). Each point 
represents mean ± SEM, n= 4 -13 experiments. *** p< 0.001: significantly different from 
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Figure 26 SX6C-induced increases in pulmonary perfusion pressure (PPP) (b) lung 
weight and (c) pulmonary inflation pressure (PIP); control (open circles) or in the 
presence of PD1450656 (0.3 pM, filled circles), (1 pM, open triangles). Each point 
represents mean ± SEM, n= 3- 13 experiments. *** p< 0.001: significantly different from 
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3.9 Effects of ET-1 and SX6C in retrogradely perfused lungs
Retrograde perfusion of lungs was used to study the sites of actions of ET-1 and SX6C 
in the pulmonary circulation. Comparative actions of ET-1 and SX6C on recorded 
parameters in orthogradely and retrogradely perfused lungs are shown in Figure 27. ET- 
1 (50-400 pmol) and SX6C (50-800 pmol) produced dose-dependent increases in PPP, 
PIP and lung weight. However, a comparison of the upper panels shows that the actions 
of ET-1 on lung weight were markedly reduced by retrograde perfusion. Using 
orthograde perfusion, 400 pmol of ET-1 produced an increase in lung weight of 6.9 ± 
0.21 g (n=4) whereas 400 pmol of ET-1 in retrograde perfusion produced only a 1.8 ± 
0.36 g (n= 4, p< 0.01) increase.
Comparison of the lower panels in Figure 27 shows that the actions of SX6C on lung 
weight were markedly increased by retrograde perfusion. Using orthograde perfusion, 
800 pmol of SX6C produced a 0.11 ± 0.06 g (n= 4) increase in lung weight whereas the 
same dose given via retrograde perfusion produced a 7.5 ± 0.29 g (n= 4, p< 0.001) 
increase in lung weight (Students t-test).
Figure 27 Experimental traces comparing the effects of ET-1 (upper section) and SX6C 
(lower section) on pulmonary perfusion pressure (PPP), lung weight (LW) and 
pulmonary inflation pressure (PIP) in rat lungs perfused orthogradely (right hand panels) 
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3.10 Albumin-bound dye extravasation
To investigate whether increases in lung weight induced by ET-1 or SX6C were due to 
changes in vascular permeability, experiments utilizing Evans blue dye linked to BSA 
were carried out. In a series of experiments the increase in lung weight caused by ET-1 
(800 pmol) was shown to be associated with a large accumulation of albumin-bound dye 
(97.5 ± 22 ng mg’1 dry weight of tissue compared to 1.32 ± 0.54 ng mg’1 in control lungs 
without ET-1; p < 0.01, n= 4). Back-calculation of fluid retention from retained dye 
indicated that 800 pmol of ET-1 caused an accumulation of 1.62 ± 0.28 ml of fluid 
(n=4). Assuming a specific gravity of 1 for this fluid a comparison of this calculated 
weight gain with weight gain recorded experimentally (4.25 ± 0.25 g, n=4) illustrates 
that the values are significantly different (p < 0.01), i.e. fluid accumulation without 
albumin. Furthermore, albumin bound dye accumulation (1.48 ± 0.85 ng mg’1 of dry wt, 
n= 4) produced by a higher dose of ET-1 (800 pmol) with retrograde perfusion was still 
significantly lower (p< 0.01) than the accumulation seen with 400 pmol ET-1 (25 ± 9.5 
ng mg'1 of dry wt., n=4) given via orthograde perfusion. Results are shown in Figure 28.
Furthermore, accumulation of albumin bound dye (216 ± 2.6 ng mg’1 dry tissue, n=4) 
caused by SX6C (800 pmol) in retrograde perfusion was significantly greater (p< 0.01) 
than albumin bound dye accumulation (70 ± 4 ng mg’1 dry wt, n=4) caused by SX6C in 
orthograde perfusion (Figure 28). Back calculation of fluid retention from retained dye 
indicated that 800 pmol of SX6C caused an accumulation of 1.44 ± 0.06 ml and 6.6 ± 
0.39 ml fluid in orthogradely and retrogradely perfused lungs, respectively (n=4). 
Assuming a specific gravity of 1 for this fluid a comparison of this calculated weight gain 
with weight gain recorded experimentally (1.46 ± 0.24 g and 7.3 ± 0.15 g, n=4, in 
orthogradely and retrogradely perfused lung, respectively) illustrates that the values are 
in good agreement.
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Figure 28 Effects of ET-1 or SX6C on vascular permeability in orthogradely (filled 
column) or retrogradely (open column) perfused lungs. Each point represents mean 
SEM, n= 4 experiments, **p< 0.01 compared with time matched control (hatched 
column).! way ANOVA.
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3.11 Effects of nitro-L-arginine (L-NOARG)
Inclusion of L-NOARG (100 pM) in the perfusate had no effect on the basal parameters 
recorded; basal PPP 5.4 ± 0.5, n=9 vs. 5.4 ± 0.6 mmHg, n=7 in control; basal lung 
weight (2.84 ± 0.12 g, n=9 vs. 2.85 ± 0.14g, n= 7 in control); basal PIP (5.24 ± 0.3 
mmHg, n=9 vs.4.15 ± 0.2 mmHg, n=7 in control).
3.11.1 Effects o f L-NOARG on responses to ETs, SX6C, and BK
3.11.1.1 PPP
From Figure 29a it can be seen that 100 pM L-NOARG potentiated PPP increases in 
response to ET-1 50 - 400 pmol (p< 0.001, n=4). Similarly, SX6 C (25-200 pmol) 
mediated increases in PPP were also significantly augmented (p< 0.001, n=5) in the 
presence of L-NOARG (Figure 30a). The maximum constrictor response to SX6 C was 
also increased in the presence of L-NOARG.
The vasoconstrictor effects of BK (6.25- 200 nmol) were potentiated by 100 pM L- 
NOARG. In the presence of L-NOARG the BK ED50 was reduced from control value of 
24 ± 4 nmol, n=7 to 16 ± 1.0 nmol, n=9. The maximum response to BK was also 
significantly increased from 10 ± 0.8 mmHg, n=7 to 14 ± 0.65 mmHg, n=9 (p< 0.01) 
(Figure 31a).
In contrast to the potentation of responses to ET-1, SX6 C and BK it was of interest to 
note that L-NOARG did not affect the increases in PPP induced by PHE (3.12- 50 nmol) 
(ED50 5.4 ± 1.7, n=3 vs. 4 ± 0.7, n=5) in controls (Figure 32a).
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3.11.12 Lung weight
In the presence of L-NOARG the lung weight increases caused by ET-1 were markedly 
potentiated (Figure 29b). Similarly SX6C-induced increases in lung weight were also 
potentiated in the presence of L-NOARG (Figure 30b).
In contrast to the potentiation of ET-1 and SX6C -induced increases in lung weight L- 
NOARG had no effect on BK-mediated increases in lung weight (Figure 31b).
3.11.1.3 PIP
Figure 29c illustrates, that the increases in PIP in response to ET-I were significantly 
augmented in the presence of L-NOARG (ED50 132 ± 5 pmol, n=4; p< 0.05 vs. 242 ± 33 
pmol, n=7 in control). Similarly, the SX6C-induced increases in PIP were also 
significantly potentiated (ED50 48 ± 5 pmol, n=5; p< 0.01 vs. 85 ± 6 pmol, n=13 in 
controls) Figure 30c.
The presence of L-NOARG did not alter the bronchoconstrictor responses to CCh (ED50 
4 ± 0.3 nmol, n=4 vs. 4.25 ± 0.4 nmol, n=7 in controls, Figure 32b) or BK (ED50 54 ± 12 
nmol, n=7 vs. 40 ± 8 nmol, n=9 in controls (Figure 31c).
Figure 29 The effects of ET-1 on (a) pulmonary perfusion pressure (PPP) (b) lung 
weight and (c) pulmonary inflation pressure (PIP) in the absence (open circles) or 
presence (filled circles) of L-NOARG (100 pM) Each point represents mean ± SEM, n=
4-7 experiments **p <0.01; ***p < 0.001 compared with control ET-1 (Students t-test).
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Figure 30 The effects of SX6C on (a) pulmonary perfusion pressure (PPP) (b) lung 
weight and (c) pulmonary inflation pressure (PDP) in the absence (open circles) or 
presence (filled circles) of L-NOARG (100 pM) Each point represents mean ± SEM,





Increase in PIP (mmHg)
o o - ^ - ^ r o h o c j G j
o
Increase in LW (g)





01 0 1 
Increase in PPP (mmHg)
—> - * 1 0 ( 0  














Figure 31 The actions of bradykinin (BK) on (a) pulmonary perfusion pressure (PPP), 
(b) lung weight (LW) and (c) pulmonary inflation pressure (PEP) in the absence (open 
circles) and presence (closed circles) of L-NOARG (100 pM)). Each point represents 




I ncrease in PIP (mmHg) Increase in LW (g)
0.5 
n
Increase  in PPP (mmHg)
o
i—
04 * CD_ i ___ K)_i_ cn
•  o
CD CD
Figure 32 The effects of (a) phenylephrine (PHE) on pulmonary perfusion pressure 
(PPP) and (b) carbachol (CCh) on pulmonary inflation pressure (PIP) in the absence 
(open circles) and presence of (closed circles) of L-NOARG (100 pM). Each point 
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3.12 Effects of ET-1 and SX6C in lungs where vascular tone is increased by 
infusion of the thromboxane A2 analogue U46619
U46619 produced concentration dependent increases in PPP (EC50 31 + 6  nM, n =3), 
lung weight and PIP (EC50 37 ± 9 nM, n =3). In subsequent experiments a concentration 
was selected to produce approximately 80 % of the maximum increase in PPP.
The infusion of U46619 (80 nM) into the pulmonary artery produced an increase in PPP 
of 9 ± 0.5 mmHg over the basal PPP of 5 ± 0.5 mmHg (n =16). Under these conditions 
with an elevated PPP bolus injections of ET-1 (2.5-40 pmol), ET-3 (2.5-80 pmol) and 
SX6 C (1.25-40 pmol) all produced dose-dependent falls in PPP (Figure 33, 34).
The vasodilator potencies of ET-1 (ED50 3.6 ± 0.6 pmol, n=5 ) and ET-3 (ED50 3.9 ± 
1.05 pmol, n =4) were similar, however SX6 C (ED50 2.2 ± 0.14 pmol, n =7; p< 0.05) 
was significantly more potent as a pulmonary vasodilator than either of the ETs.
Figure 33 Experimental traces showing the elevation of basal pulmonary perfusion 
pressure (PPP) with U46619 (80 nM) and the fall in PPP in response to (a) ET-1, (b) 
ET-3 and (c ) SX6C. Each trace represents one of 4-7 such experiments.
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Figure 34 Graph showing the pulmonary vasodilator responses to ET-1 (open circles), 
ET-3 (filled circles) and SX6C (open triangles) in lungs in which perfusion pressure had 
been increased withU46619. Each point represents mean ± SEM, n= 4-7 experiments.
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3.12.1 Effect o f cyclooxygenase inhibitor and ET receptor antagonist on vasodilator 
responses to ET-1 and SX6C
In many other vascular preparations the vasodilator responses to ETs and SX6 C has 
been reported to be partially mediated by cyclooxygenase and nitric oxide synthase 
metabolites (Warner et al., 1989; Ekelund et ai., 1994). Therefore, experiments were 
carried out to examine this in lungs.
3.12.1.1 Indomethacin
Inclusion of the cyclooxygenase inhibitor indomethacin (10 pM) did not alter basal PPP 
(5.6 ± 0.6 mmHg, n=7) or the increase in PPP produced by U46619 (80 nM) (PPP of 10 
± 0.7 mmHg, (n=7) vs. 9 ± 0.5 mmHg, (n= 16) in controls). However, indomethacin did 
reduce the vasodilator response to low doses of ET-1 (1.25-5 pmol), whereas responses 
to higher doses of ET-1 (5- 20 pmol) were not affected (Figure 35b). Accumulated 
results are shown in Figure 37a. ET-1 ED50 vasodilator value was significantly increased 
to 9 ± 3.4 pmol, n=3 (p< 0.05) vs. 3.6 ± 0.6 pmol, n=5 in controls. In contrast, 
indomethacin (10 pM) augmented the decrease in PPP in response to low doses of SX6 C 
(1.25-2.5 pmol). However, responses to higher doses (5-20 pmol) of SX6 C were not 
altered Figure 36b. SX6 C ED50 (1.7 ± 0.3 pmol, n=4) vasodilator value was not different 
to the control value quoted above. Accumulated results are shown in Figure 37b.
3.12.1.2 L-NOARG
The nitric oxide synthase inhibitor L-NOARG (100 pM) had no effect on basal PPP (5 ± 
0.4 mmHg, n=8 ). However it augmented PPP increases in response to U46619.
Therefore a lower concentration of U46619 was used in order to elevate the PPP by a 
similar amount seen earlier approximately 9 mmHg.
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In a series of experiments 40 nM of U46619 produced an increase in PPP of 8.5 ± 0.8 
mmHg, n=8. Figure 35c illustrates that in the presence of L-NOARG a low dose of ET-1 
(1.25 pmol) produced vasodilation, whereas, at higher doses (5-20 pmol) vasoconstrictor 
responses were seen. Accumulated results from 4 different experiments are shown in 
Figure 38.
In a different set of experiments perfusion of indomethacin (10 pM) and L-NOARG (100 
pM) in combination had no effect on basal PPP (5 ±0.5 mmHg, n=3) or the increase in 
PPP in response to U46619 40 nM (10.6 ± 1.3 mmHg, n=4). However, this combination 
of inhibitors completely abolished the vasodilator response to ET-1, whereas 5- 20 pmol 
of ET-1 now produced marked rises in PPP. Accumulated results from 3 different 
experiments are shown in Figure 38.
In contrast to ET-1-induced vasodilation the vasodilator responses to SX6C (1.25-20 
pmol) were completely abolished in the presence of L-NOARG (100 pM). The highest 
dose of SX6C (20 pmol) now produced an increase in PPP (Figure 36c). Accumulated 
results are shown in Figure 39.
Perfusion of L-NOARG (100 pM) had no effect on vasodilation produced by the nitric 
oxide donor sodium nitroprusside (SNP) 10-1000 pmol (Figure 40). This shows that the 
effects of L-NOARG on ET-1 and SX6C responses were not due to non-specific action.
3.12.1.3 Nitro-D-arginine (D-NOARG)
To check the stereoselectivity of L-NOARG, experiments were carried out in the 
presence of the inactive isomer D-NOARG. Inclusion of D-NOARG (100 pM) into the 
perfusate had no effect on basal PPP (5 ± 0.6 mmHg, n=8) or the rise in PPP (9.2 ± 0.9 
mmHg, n= 8 vs. control value quoted above) in response to U46619 (80 nM). Similarly, 
D-NOARG did not alter the vasodilation produced by ET-1 (2.5- 40 pmol) (Figure 35e) 
or SX6C (1.25- 40 pmol) (Figure 36d).
Accumulated results are shown in Figure 38 and 39. ED50 values for ET-1 and SX6C in 
the presence and absence of D-NOARG were ET-1, 3.2 ±1.2 pmol, n=4 vs. 3.6 ± 0.6 
pmol, n=5 in controls and SX6C, 2.3 ± 0.6 pmol, n=4 vs. 2.2 ± 0.14 pmol, n=7 in 
controls.
Figure 35 Experimental traces showing the elevation of basal pulmonary perfusion 
pressure (PPP) with U46619 (40-80 nM) and the subsequent changes in PPP in response 
to ET-1 in (a) control, (b) in the presence of indomethacin (10 pM), (c) in the presence 
of L-NOARG (100 pM ), (d) in the presence of indomethacin (lOpM ) plus L-NOARG 
(100 pM ) and (e) in the presence of D-NOARG (100 pM). Each trace is representative 
of 3-5 similar experiments.
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Figure 36 Experimental traces showing the elevation of basal pulmonary perfusion 
pressure (PPP) with U46619 (40-80 nM) and the subsequent changes in PPP in 
responses to SX6C (a) control (b) in presence of indomethacin (10 pM) (c)in the 
presence of L-NOARG (100 pM) and (d) plus D-NOARG (100 pM). Each trace is one 
of 4-7 similar experiments.
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Figure 37 Graphs showing the pulmonary vasodilator response to (a) ET-1 and (b) 
SX6C in the absence (open circles) and presence (filled circles) of indomethacin (10 
pM) in U46619 pre-treated preparations. Each point represents mean ± SEM, n= 3-7 
experiments. *p< 0.05 (Students t-test).
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Figure 38 Graph showing the pulmonary vascular responses to ET-1: controls (open 
circles), in the presence of D-NOARG (100 pM) (open squares), L-NOARG lOOpM 
(filled circles)and indomethacin (10 pM) plus L-NOARG (100 pM) (filled triangles) in 
U46619 pre-treated preparations. Each point represents mean ± SEM, n=4-5.
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Figure 39 Graph showing the pulmonary vascular responses to SX6C controls, n= 7 
(open triangles), and in the presence of; D-NOARG (100 pM), n= 4 (open squares), L- 
NOARG lOOpM, n= 4 (filled triangles), in U46619 pre-treated preparations. Each point 
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Figure 40 Graph showing the pulmonary vasodilator responses to sodium nitroprusside 
(SNP) in the absence (open circles) or presence (filled circles) of L-NOARG (100 pM) 
in U46619 pre-treated preparations. Each point represents mean ± SEM, n= 4
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3.12.1.4 BQ123 (selective ETA receptor antagonist)
Inclusion of BQ123 (10 pM) in the perfusate did not alter basal PPP or the increase in 
PPP in response to U46619 (80 nM), n=3.
Figure 41b illustrates, that in U46619 preconstricted preparations BQ123 was without 
any marked effect on the vasodilator responses to ET-1 (2.5-40 pmol). Accumulated 
results are shown in Figure 42a (ET-1 ED50 5.6 ± 1 pmol, n=3 vs. 3.6 ± 0.6 mmHg, n=
5 in controls).
3.12.1.5 Bosentan (Ro47-0203, mixed endothelin ETA / ETB receptor antagonist)
The effects of the mixed ETa/ETb receptor antagonist bosentan were studied on 
pulmonary vasodilator responses to ET-1 and SX6 C. Perfusion of bosentan (5 pM) had 
no effect on basal PPP (5.1 ± 0.5 mmHg, n=8 ). The infusion of U46619 (80 nM) 
produced an increase in PPP of 9.25 ± 0.6 mmHg, n=8 . Figure 41c and 41e illustrate that 
bosentan completely abolished (p< 0.001) the decreases in PPP produced in response to 
ET-1 (1.25- 40 pmol) or SX6 C (1.25 - 40 pmol). Accumulated results are shown in 
Figure 42.
To check the selectivity of actions, the effects of bosentan on SNP-induced pulmonary 
vasodilator responses were examined. Bosentan (5 pM) had no effect on SNP-induced 
decreases in PPP (100 pmol of SNP in the presence of bosentan produced fall in PPP of 
28 % ± 4, n=3 vs. 27 % ± 2 in control lungs).
Figure 41 Experimental traces showing the falls in PPP in response to ET-1; (a) control, 
(b) in the presence of BQ123 (10 pM), (c) in the presence of bosentan (5 pM). SX6C ; 
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Figure 42 Graphs showing the pulmonary vasodilator responses to (a) ET-1) (b) SX6C 
alone (open circles)or in the presence of BQ123 ( 10 pM ) (filled circles) or bosentan (5 
pM) (open triangles) in U46619 pre-treated preparations. Each point represents mean ± 
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3.13 Tachyphylaxis to ETs and SX6C
Although dose-response curves to the vasodilator effects of ET-1 and SX6C could be 
constructed, it was noted that repeated injections of the dose which produced a 
maximum vasodilation, caused rapid loss of response. Therefore, a series of experiments 
were carried out to study this phenomena in more detail. In these experiments the 
infusion of U46619 (80 nM) produced an increase in PPP of 9 ± 0.6 mmHg, n=3.
The effects of several repeated injections of ET-1 or SX6C (20 pmol each) are shown in 
Figure 43. As shown the dilator responses to ET-1 (Figure 43a) and SX6C (Figure 43b) 
given repeatedly at 5-7 min intervals showed a marked tachyphylaxis. As can be seen, the 
fifth dose of ET-1 (panel A) actually produced vasoconstriction rather than a vasodilator 
response. The final portion of the recording shows that injection of a series of doses of 
SX6C after the ET-1 injections also produced dose-dependent increases in PPP. This 
contrasts markedly with the results shown in panel B of Figure 43 where SX6C injected 
before ET-1 caused marked depressor responses which decreased in magnitude with 
repeated injections. As can be seen, the sixth injection actually produced a 
vasoconstrictor as opposed to a vasodilator response. Subsequent injections of ET-1 
now caused dose-dependent increases in PPP. Accumulated data is shown in Figure 44.
Figure 43 Experimental traces showing the tachyphylaxis /  cross tachyphylaxis of the 
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Figure 44 Histogram showing the tachyphylaxis to the pulmonary vasodilator responses 
to ET-1 (filled columns ) and SX6C (open columns) in U46619 pre-treated preparations. 
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Isolated perfused lungs have been used for a long time to study aspects of pulmonary 
function. However, no generally accepted criteria for the viability of such preparations 
have yet been defined. The present experiments have showed that under the conditions 
described this model is viable for 2 h as; (a) there was no increase in lung weight noticed 
within this period indicating that lung integrity was not altered, moreover PPP and PIP 
remained stable, (b) the responses to PHE, CCh, BK and angiotensin-I were 
reproducible indicating that reactivity to various agonists was not changed within this 2 h 
of perfusion time, (c) the metabolic capability of the endothelial cells was preserved, as 
the responses to angiotensin-I reappeared after the angiotensin converting enzyme 
inhibitor captopril was washed out.
A single-pass perfusion model was utilised rather than a recirculating one as any 
substance robust enough to survive passage through the pulmonary circulation would 
continue to act in_the latter, making quantitation of effects complex. Using single-pass 
perfusion also avoids accumulation of any products released by the lungs into the 
perfusate which could influence lung function. In this lung preparation plasma expanders 
were not included into the perfusate because of the cost. However, in many previously 
described lung preparations recirculation procedures have been used in the presence of 
plasma expander such as dextran, albumin, ficoll, etc. (Selig et al., 1988; Drazen et al., 
1989; Westcott et al., 1990; Czartolomna et al., 1991; Seale et al., 1991; Bonvallet et 
al., 1993; Pino et al., 1992; Uhlig and Wollin, 1994) to offset oedema in lung models.
Rate of perfusion is easily varied and is usually a "trade-off between maintaining tissue 
viability yet avoiding higher rates which increase the rate of oedema formation through 
hydrostatic damage. Results from the present study indicate that even at low rates of 
perfusion (5 ml m in'l) lung integrity is relatively short-lived as increases in lung weight 
started to occur after 2h of perfusion. Use of higher flow rate (10 ml min"1) in this model 
produced quick oedema formation. Fisher et al., (1980) have also shown that rat lungs 
perfused at 12-25 ml min-1 with Krebs' solution alone developed gross alveolar oedema
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after 1 h and the addition of 3 % bovine serum albumin at these higher flow rates 
increased the lung viability to 2-3 hours.
In the present model lungs were ventilated at a volume and rate which did not cause any 
significant increase in lung weight over 2 h, as even moderate overinflation is known to 
cause lung injury (Cilley et al., 1993). In addition, investigators have suggested that 
overinflation of the lung can lead to stress failure, a cause of increased capillary 
permeability and pulmonary oedema (West and Mathieu-Costello, 1992).
4.1 Differential effects ofPH E, CCh, and BK
In order to evaluate the actions of vasoactive agents on the three monitored lung 
parameters initial experiments were carried out by using PHE, CCh and BK. Experiments 
showed that under the conditions described these three substances exerted differential 
pulmonary vascular and bronchial effects. PHE-produced selective dose-related increases 
in PPP, CCh-produced dose-dependent increases in PIP without having any effect on 
PPP and lung weight, whereas BK-produced dose-related increases in PPP, lung weight 
and PIP.
Indomethacin did not alter any of the basal parameters recorded suggesting that 
cyclooxygenase products do not play a major role in regulating basal pulmonary vascular 
or bronchial smooth muscle tone. Indomethacin also had no effect on the pulmonary 
vascular and bronchial responses to PHE and CCH or BK respectively. However, it 
significantly potentiated the increase in the PPP response to the highest dose of BK but 
responses to lower doses, and the ED50 values were not affected by indomethacin. This 
suggests that the release of cyclooxygenase products is not a major factor in lung 
responses to PHE, CCH and low doses of BK. However, the higher doses of BK may 
produce the release of vasodilator prostanoids which would inhibit the vasoconstrictor 
effects of BK. In another report the cyclooxygenase inhibitor aspirin potentiated the BK- 
induced responses in vivo (Bhoola et al., 1962). BK has been reported to release
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prostacyclin from the perfused lung preparation (Bakhle et al., 1985), which can produce 
relaxations of porcine isolated pulmonary blood vessels (Zellers et al., 1994). Therefore, 
inhibition of PGI2 production by indomethacin could explain why it potentiated the 
constrictor actions of higher doses of BK.
In the present experiments the pulmonary vasoconstrictor action of PHE was 
antagonized by a selective a x-adrenoceptor antagonist prazosin. Previous reports have 
demonstrated the presence of ccp adrenoceptors on the isolated pulmonary blood vessels 
and in the pulmonary vascular bed of rabbit, cat, and dog (Barnes and Liu, 1995). The 
bronchoconstrictor action of CCh was markedly attenuated with atropine suggesting that 
the action of CCh is mediated via activation of muscarinic receptors (Post et al., 1991).
The selective BK2 receptor antagonist D-Arg-[Hyp3, Thi5’8, D-Phe7]-bradykinin (Regoli 
etal., 1986; Schachter et al., 1987; Steranka et al., 1989) inhibited BK-induced 
increases in PPP and lung weight and PIP suggesting that the responses to BK are 
mediated via activation of BK2 receptors. These findings are in agreement with a recently 
reported BK receptor binding investigation in rat lung membranes in vivo and in vitro 
(Tsukagoshi et al., 1995). Studies in other vascular beds have shown that BK2 receptors 
are located on the venous smooth muscles which mediate the permeability effects of BK 
(Murray et al., 1991). D-Arg-[Hyp3, Thi5,8, D-Phe7]-bradykinin also blocks BK- induced 
vascular permeability in rabbit skin in vitro (Schachter et al., 1987). Similarly, BK2 
receptors have been reported in human isolated bronchi (Molimard et al., 1995) and 
guinea pig lung parenchyma (Lach et al., 1994).
4.1.2 Pulmonary perfusion pressure and lung weight
PHE was more potent in producing increases in PPP than BK. This is possibly because of 
extensive inactivation of BK which occurs in the pulmonary circulation (Alabaster and 
Bakhle, 1972; Baker et al., 1992; Pesquero et al., 1992;). The potency of BK was 
significantly increased in the presence of captopril.
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The increases in PPP produced by PHE were not associated with changes in lung weight 
Although BK also increased PPP such a precapillary action of BK is unlikely, as BK is 
known to produce potent arteriolar vasodilation in many vascular beds (Bonner et al., 
1990; Feletou et al., 1995). Toda (1977) showed that BK tends to relax arterial smooth 
muscle and constrict venous smooth muscle both in human and animals. In the present 
model the increases in PPP seen with low doses of BK were associated with reversible 
increases in lung weight whereas, at higher doses, BK produced irreversible increases in 
lung weight. Experiments have shown that albumin-bound dye was not retained with the 
low dose of BK but higher doses did increase permeability as shown by accumulation of 
albumin-bound dye.
A clue to the site of vasoconstrictor action of PHE and BK comes from examining the 
changes in lung weight. Arteriolar constriction would not increase capillary pressure and 
would not be expected to cause hydrostatic oedema. In contrast, venular constriction 
would increase capillary pressure and this would be expected to produce hydrostatic 
oedema. The fact that PHE did not increase lung weight would therefore suggest an 
arteriolar site of action, while the BK-induced increase in lung weight would suggest a 
venular constrictor action.
The major questions which arise from the vascular actions of BK are whether BK- 
induced oedema results from; (1) a direct action on capillary membrane permeability, or 
(2) indirectly from actions on vascular smooth muscle causing hydrostatic changes due to 
opening of previously unperfused vessels, or (3) a combination of both such effects. In 
order to determine which of these factors were responsible, the effects of BK on lung 
weight were examined; (a) in retrogradely perfused lungs and (b) in the presence of a 
vasodilator papaverine.
The results showed that in retrogradely perfused lungs the increases in PPP produced by 
BK were not different to those produced by a similar dose of BK given via the 
orthograde route. However, there was -50% reduction in weight gain compared to
weight gain produced by BK when given in the orthogradely perfused lungs. This 
suggests that when given via the orthograde route BK-induced increases in lung weight 
were partially mediated via its constrictor action on the venous side of the pulmonary 
circulation leading to a hydrostatic increase in lung weight. Other reports have also 
suggested that the venoconstrictor effects of BK contribute to oedema formation in 
many vascular beds (Rowley, 1964; Bonner et al., 1990). In the present experiments 
such venoconstriction could explain the reversible increase in lung weight seen with low 
doses of BK, the reversibility being a response of the compliance of the capillary bed. 
This would reverse as the effect of BK at its receptor sites declined due to rapid 
inactivation of BK in the pulmonary circulation. At higher doses the compliance of the 
microcirculation would be exceeded and fluid would be forced into the interstitial space 
leading to oedema formation. Furthermore, at high doses BK would evoke more 
powerful venoconstriction which, aside from mere increased hydrostatic sieving, might 
accelerate egress of liquid from the vasculature via an increase in permeability or in 
permeable surface area. Powerful venoconstriction, might lead to a hydrostatically- 
mediated permeability increase (Rowley, 1964). Alternatively, higher doses of BK may 
cause contraction of the endothelial cells of capillary and post-capillary venules and open 
up junctions between cells as has been reported to occur in the bronchial circulation 
(Ichinose and Barnes, 1990; Sakamoto et al., 1992) and this would also increase vascular 
permeability. BK is reported to contract actomyosin elements located within the 
endothelial cells which results in the formation of large venular gaps which form at cell 
junctions in venules subsequent to cell separation owing to a “rounding up” of the ends 
of adjacent endothelial cells (see Grega et al., 1982). Furthermore, reversible 
modulation may occur within seconds in response to specific agents and involve 
activation of the contractile apparatus i.e. activation of actin and myosin system in the 
endothelial cells (Crone, 1986). Another possibility is that high intravascular pressures 
could also increase total perfused surface area through recruitment of poorly-perfused or 
unperfused vessels (Hyman et al., 1967), this may enhance egress of liquid and albumin 
from the vasculature in the presence or absence of increased permeability per se.
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In a different approach, the effects of BK on lung weight were investigated in the 
presence of the vasodilator papaverine, in order to see whether lung weight changes 
associated with BK were secondary to increases in PPP. Results showed that, papaverine 
reduced the increases in PPP and lung weight in response to BK. This supports the 
hypothesis that the increase in lung weight in response to BK is linked to its 
vasoconstrictor actions.
In addition, VOP was raised in order to investigate if increases in VOP would produce 
similar changes in lung weight to those seen with BK. It was shown that when VOP was 
raised (5-15 mmHg) for 1 min it produced increases in PPP which were associated with 
reversible increases in lung weight At higher levels of VOP (20-25 mmHg) increases in 
PPP were associated with irreversible increases in lung weight suggesting that there may 
be a threshold pressure which when exceeded produces irreversible changes in lung 
weight. Guyton and Lindsey, (1959) have reported that increments of left atrial pressure 
had little effect on the fluid content of dog lung tissue until the pressure exceeded 25 
mmHg. They have also suggested the that the pressure above which fluid accumulation 
in the lung becomes sensitive to left atrial pressure should be called the "critical 
pressure". When VOP was raised to 20 mmHg the irreversible increase in lung weight 
was also associated with a marked retention of albumin-bound dye. This suggests that an 
increase in VOP alone can increase vascular permeability increases to albumin. This is in 
agreement with the findings of Sakai et al., (1989) who also reported increased albumin 
escape when outflow pressure was elevated. In rabbit lung preparations the limit of VOP 
elevation not leading to outward filtration was 5 to 10 mmHg (Hauge and Nicolaysen, 
1971). Retention of albumin bound dye caused with elevated VOP could be explained 
due to the fact that the increase in pulmonary capillary pressure stretches the pores 
through which fluid and protein traverse the capillary wall, thereby accounting for high 
rates of fluid and protein accumulation at high capillary pressure (Michel, 1994). The fact 
that increases in VOP to levels which induce changes in PPP similar to those produced 
by 200 nmol of BK caused a significant albumin-bound dye accumulation suggests that 
the weight increase induced by VOP is not due to hydrostatic sieving across a normally
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permeable vasculature but that VOP like BK, may increase permeability (Sakai et al., 
1989) and / or permeable surface area.
4.1.3 Pulmonary inflation pressure
The present experiments have shown that both CCH and BK when administered into the 
pulmonary artery produced increases in PIP, indicative of bronchoconstriction. However, 
the bronchial region normally receives its main blood supply from the tracheo-bronchial 
arteries which arise from the systemic arterial circulation (Marchand et al., 1950; 
Deffebach et al., 1987) which is not perfused in this model. This suggests that either a 
proportion of the bronchial smooth muscle receives perfusate via the pulmonary artery or 
that there may be anastomoses between the pulmonary and the tracheobronchial 
microvessels (Kroll et al., 1987). Indeed, pulmonary artery forming anastomoses have 
been shown in the rat pulmonary circulation (McLaughlin et al., 1966; McLaughlin et 
al., 1983). Perfusion of the pulmonary artery with fluorescein isothiocyanate-dextran ( 
FITC-D) (Kroll et al., 1987) led to the presence of FITC-D in the tracheobronchial 
tissue. Therefore, it is possible that in the present study the flow from the pulmonary to 
the airway circulation is via these microvascular anastomoses.
The maximal bronchoconstrictor effects achievable with CCh and BK were similar but 
CCh was more potent than BK. Results have shown that the bronchoconstrictor potency 
of BK was markedly increased in the presence of captopril which again indicates that the 
activity of BK is being attenuated by angiotensin converting enzyme. Increases in PIP in 
response to CCh were fully reversible at all doses but this was only true with smaller 
doses of BK. In addition at higher doses BK also produced vascular leakage as indicated 
by the Evans blue study and the appearance of fluid in the tracheal cannula. Therefore it 
is possible that the residual irreversible increase in PIP induced by BK is secondary to 
increased vascular permeability resulting in fluid accumulation in the interstitial space, the 
airways or the alveoli (Bachofen et al., 1993). BK-induced airway exudation has also 
been reported by other investigators.(Arakawa et al., 1992; Hui et al., 1992; Yokoyama
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et al., 1993). The increased basal PIP caused by BK may therefore result from 
mechanical resistance caused by fluid in the airway. The fact that increases in VOP which 
caused irreversible increases in lung weight also increased PIP with associated fluid 
accumulation supports this hypothesis.
4.2 Endothelins and sarafotoxin 6c
Having validated the perfused lung model utilising the agonists discussed above 
experiments were then undertaken to investigate the effects of ETs and SX6C in this 
preparation.
4.2.1 ET receptors- mediating pulmonary vasoconstriction
In this perfused lung preparation ET-1, ET-2 and ET-3 produced dose-dependent 
increases in PPP suggesting ETs induced pulmonary vasoconstriction. These findings are 
in agreement with those reported in the other rat lung preparations (Rodman et al., 1992; 
Bonvallet et al., 1993; Hisaki et al., 1994a; Hisaki et al., 1994b) and rat isolated 
pulmonary blood vessels (Wanstall and O'Donnell, 1990; Rodman et al., 1992; Bonvallet 
et al., 1993; MacLean et al., 1994). The present data also supports previous studies in 
human isolated pulmonary blood vessels (McKay et al., 1991; Hay et al., 1993; Buchan 
et al., 1994; Maguire and Davenport, 1995). The fact that the pulmonary vasoconstrictor 
potencies of Ets are ET-1> ET-2 >ET-3 suggests an action mediated via ETA receptors 
(Webb, 1991). This was further supported by the findings that a selective ETA receptor 
antagonist BQ123 (Ihara et al., 1992) caused a concentration-dependent inhibition of the 
pulmonary vasoconstrictor responses to ET-1. Previous studies using isolated 
pulmonary arteries have shown that ETs- induced contractions were inhibited in the 
presence of the selective ETA receptor antagonists BQ123 or FR139123 (Bonvallet et 
al., 1993; Sogabe et al., 1993). The fact that higher concentrations of BQ123 (lOpM) 
significantly reduced the maximum increase in PPP induced by ET-1 indicates that
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BQ123 may act as a non-competitive antagonist at ETA receptors. A similar observation 
has been reported by Hiley et al., (1992).
The finding that a low concentration of BQ123 (1 pM) potentiated the increase in PPP 
to the highest dose of ET-1 may indicate the presence of different subtypes of ETA 
receptor in the pulmonary circulation, one situated on smooth muscle mediating 
contraction, the second situated on the endothelium which on activation releases a 
vasodilator substance (s) in response to ET-1. The blockade of this component of the 
response in the presence of low concentration of BQ123 could account for the 
potentiation of the vasoconstrictor response to ET-1. Previous findings have shown that 
ET-1-induced release of the vasodilator prostanoid PGI2 in isolated perfused rat lung is 
blocked in the presence of 1 pM BQ123 (D'Orleans-Juste et al., 1992; D'Qrleans-Juste et 
al., 1993a). However, in the present experiments indomethacin did not alter ET-1- 
induced vasoconstriction. Interestingly, other studies have shown that ET-1 dose- 
dependently stimulates cAMP formation in vascular smooth muscle cells and this was 
blocked by BQ123 (Eguchi et al., 1993). Therefore, it is possible that activation of such 
an ETa receptor subtype increases cAMP levels which could then oppose ET-1-induced 
vasoconstriction. Potentiation of constrictor responses to ET-1 in the presence of BQ123 
has also been reported in other vascular preparations (Comet et al., 1993).
The fact that higher concentrations of BQ123 (2- 10 pM) markedly blocked the ET-1- 
induced increase in PPP suggests that at higher concentrations BQ123 is blocking the 
ETa receptor subtype which is responsible for the vasoconstrictor actions. The present 
data also shows that BQ123 had no effect on the vasoconstriction produced by SX6C 
indicating that at the concentrations used BQ123 is not producing non-selective 
blockade of ET receptors in this model.
SX6C, a highly selective ETB receptor agonist (Williams et al., 1991) was also found to 
be a pulmonary vasoconstrictor with a potency similar to ET-1. Thus stimulation of ETB2 
receptors can also produce vasoconstriction in the lung, a similar finding has been
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reported in guinea-pigs (Noguchi et al., 1993). In addition ETb2 receptors have been 
shown to be present on isolated rings of rat pulmonary arteries (MacLean et al., 1994).
In the present model ET-1 at low doses produced sustained vasoconstriction, whereas, at 
higher doses it caused a biphasic effect, a transient increase followed by a sustained 
increase in PPP. In contrast ET-3 and SX6C produced only a transient increases in PPP. 
This may indicate that the biphasic vasoconstriction produced by ET-1 could be due to 
the activation of different ET receptors sub-types in the pulmonary vascular bed. The 
fact that ET-1 has a high binding affinity for the ETA receptor could explain the sustained 
rise in PPP (Noguchi et al., 1993). This was further supported by the finding that in the 
presence of BQ123 ET-1 caused only a transient vasoconstriction which is probably due 
to the activation of ETB2 receptors. Interestingly, it has been shown in receptor binding 
studies that ET-1 remains bound to ETA receptors for a prolonged time and continues to 
activate a signal-transducing G protein, which accounts for the sustained contractions 
induced in smooth muscle (Chun et al., 1995).
In the present experiments perfusion of the mixed ETA / ETb receptor antagonists 
bosentan,' or PD145065, (Doherty et al., 1993; Clozel et al., 1994), blocked the 
responses to ET-1 and SX6C on PPP confirming that pulmonary vasoconstriction is 
mediated via both ETA and ETB2 receptors. More recently a similar finding has been 
reported by Eddahibi et al., (7995). Furthermore, in vivo experiments have shown that 
bosentan, or PD145065, decreased the pressor responses to ET-1 and SX6C in rat and 
guinea pig (Clozel et al., 1994; Filep et al., 1994; Teerlink et al. 1995; Warner et al., 
1995). The fact that bosentan, or PD 145065, were both more potent in blocking PPP 
increases induced by ET-1 compared to SX6C suggests that both of these antagonists 
are more potent in blocking ETA receptor mediated vasoconstriction as compared to 
ETB2 mediated responses. This is in agreement with the reported potency profile which 
shows that bosentan is 20-50 fold selective for the ETA receptors compared with ETB 
receptors (Clozel et al., 1994). In addition, previous reports have shown a lower IC50 
value of PD 145065 for ETA receptors compared to ETB receptors (Doherty et al.,
1993). The fact that bosentan, or PD 145065, had no effect on the PHE-induced 
vasoconstrictor responses suggests that these antagonists are acting selectively at ET 
receptors.
The neutral endopeptidase inhibitor phosphoramidon (1 pM) had no effect on basal 
monitored parameters. However, phosphoramidon significantly potentiated ET-3- 
induced increases in PPP which suggests that ET-3 is inactivated by a phosphoramindon 
sensitive enzyme (probably neutral endopeptidase) present in the lung tissue (Battistini et 
al., 1995). Similar findings have been reported in isolated airways of rabbit and human 
(McKay et al., 1992), and in guinea pig lung parenchyma (Battistini et al., 1995). The 
fact that SX6C-induced responses were not altered in the presence of phosphoramindon 
indicates that ETs are more susceptible to breakdown by neutral endopeptidase present 
in the lung than SX6C (Sokolovsky et al., 1990).
4.2.2 ET-induced pulmonary oedema
Results indicated that ETs are also very potent in producing increases in lung weight, 
which supports the findings of Ercan et al., (1993). The potency profile of ETs in 
causing increases in lung weight paralleled their vasoconstrictor potencies (ET-1> ET-2 
> ET-3) which suggests that changes in lung weight are secondary. This is further 
supported by the fact that in the presence of the vasodilator papaverine, ET-1-induced 
vasoconstriction and lung weight increases were abolished. Interestingly SX6C produced 
similar increases in PPP to that of ETs but caused very little increase in lung weight.This 
raises the possibility of a differential distribution of ET receptor subtypes within the 
pulmonary vascular bed.
As shown earlier PHE selectively increased PPP whereas BK increased both PPP and 
lung weight. These different effects were explained by PHE producing arteriolar 
vasoconstriction whereas BK-caused venoconstriction. Thus SX6C, like PHE could be 
acting on the arteriolar side of the pulmonary circulation whereas ETs, acting like BK-
154
cause venoconstriction, an action ETs are known to exert (Horgan et al., 1991; Rodman 
et al., 1992), and oedema formation.
Previous studies using rat isolated pulmonary blood vessels have shown that veins are 
more sensitive than arteries to ET-1 (Rodman et al., 1992). In another report Raj et al.,
(1992) showed that ET-1 predominantly constricted pulmonary veins. In order to 
investigate this possibility, retrograde perfusion was used. Under these conditions 
arterial vasoconstriction will now cause an increase in hydrostatic pressure within the 
microcirculation, and increase lung weight via hydrostatic means, whereas venous 
constriction would be expected to cause little effect on lung weight because the 
microvascular pressure would not be significantly altered. This is exactly what was 
found. With retrograde perfusion SX6C now produced significant increases in lung 
weight, whilst ET-1 had a reduced effect on lung weight, suggesting that the ETB2 
receptors stimulated by SX6C are predominantly located on the arterial side of the 
pulmonary circulation whereas the majority of ETa receptors appear to be located on the 
venous vessels. These results agree with findings in other vascular beds (D'Orleans-Juste 
et al., 1993b; White et al., 1993; MacLean et al., 1994).
Results in the present experiments have also shown that increases in lung weight 
produced by ET-1 are associated with a large accumulation of albumin bound dye. When 
ET-1 was given via orthograde perfusion it produced a marked accumulation of albumin 
bound dye, whereas when given retrogradely, significantly less dye retention was seen. 
These findings further support the suggestion that increases in lung weight and retention 
of dye produced with ET-1 are due to potent venoconstriction. Furthermore, increases in 
lung weight resulting from fluid accumulation were significantly higher than the expected 
lung weight increases calculated from the retention of dye. This suggests that 
accumulation of fluid in the lung is primarily due to hydrostatic oedema rather than to a 
direct increase in vascular permeability to albumin. When SX6C was given using 
orthograde perfusion it also caused retention of albumin bound dye which indicates the 
presence of some ETB2 receptors mediating constriction of pulmonary venous smooth
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muscle which would contribute to the pulmonary oedema via a hydrostatic mechanism. 
However, when SX6C was given retrogradely it produced a significantly higher 
retention of albumin bound dye compared to orthograde perfusion. This provides further 
evidence that the majority of ETB2 receptors are located at the arteriolar level.
The potency profile of ETs in increasing lung weight suggests a role for ETA receptors. 
This is supported by the findings that a selective ETA receptor antagonist, BQ123, 
produced a concentration -dependent blockade of ET-1-induced lung weight responses. 
In vivo investigations in many organs have also shown that ET-1-mediated albumin 
extravasation is attenuated by another selective ETA receptor antagonist, FR139317, 
(Filep et al., 1993; Filep et al., 1994). However these findings are not in agreement with 
those of Bonvallet et al., (1993), who showed that in the rat isolated perfused lung, ET-1 
associated hydrostatic oedema was unaffected by BQ123. This may be due to different 
experimental conditions as the latter study used a recirculating model which was 
complicated by periods of hypoxia and angiotensin-II addition. The fact that SX6C- 
induced increases in lung weight were not blocked by BQ123 also suggests that a small 
population of ETB2 receptors activated by SX6C are also present on the venous smooth 
muscle.
In the present model the mixed ETA/ ETB receptor antagonists, bosentan (Clozel et al., 
1994) and PD 145065, both blocked the lung weight increases produced by ET-1 or 
SX6C. This again supports the suggestion that both ETA and ETB2 receptors play a role in 
mediating ET-1 and SX6C -induced lung weight responses. In another study it has been 
reported that both ET-1, or IRL1620 (another ETB receptor agonist), in vivo, caused 
albumin extravasation in many vascular organs by the activation of both ETA and ETB 
receptors (Filep et al., 1994).
The finding that phosphoramidon markedly potentiated the increase in lung weight 
produced by ET-3, while having no significant effect on SX6C -induced lung weight 
changes, suggests that degradation of ET-3 in the lung by endopeptidase may reduce the
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effects of ET-3, whereas SX6C is resistant to breakdown by endopeptidases (Sokolovsky 
et al., 1990). Phosphoramidon -sensitive degradation of ET-3 has also been reported in 
guinea pig lung parenchymal strips (Battistini et al., 1995). The cyclooxygenase inhibitor 
indomethacin had no effect on the lung weight increases produced in response to ET-1 or 
SX6C. This suggests that prostanoids do not play any role in the effects of ET-1 or SX6C.
4.2.3 Receptors mediating bronchial actions o f ETs and SX6C
The bronchoconstrictor potency profile of ETs (ET-1* ET-2 * ET-3) and SX6C 
suggests an ETb2 mediated response in bronchial smooth muscle. Previous evidence in 
guinea pig lung parenchymal strips has shown that ETs -induce contractions via ETB2 
receptors (Hay et al., 1993). It has also been reported that ET-l-induced guinea pig 
tracheal contractions are not affected in the presence of the ETa receptor antagonist 
FR139317 (Cardell et al., 1993).
The fact that BQ123, at concentrations which reduced ET-l-induced increases in PPP 
and oedema, did not produce any reduction in the bronchoconstrictor effects of ET-1 or 
SX6C shows that bronchoconstriction was unlikely to1'be mediated by ETA receptors. 
Similar findings have been reported in the guinea pig (Hay et al., 1993; Battistini et al., 
1994) and in human bronchus (Hay et al., 1993). SX6C was more potent than the ETs 
in causing bronchoconstriction, and the slope of the SX6C dose-response-curve was 
significantly steeper, and achieved a higher maximum than that of ETs . This could be 
due to a number of factors. Firstly, ETs are known to be more susceptible than SX6C to 
breakdown by neutral endopeptidase present in the lung, this would reduce the effects of 
ETs compared with SX6C (Sokolovsky et al., 1990). However, this was discounted as 
the bronchoconstrictor actions of ETs were not influenced by the addition of the neutral 
endopeptidase inhibitor phosphoramidon. A recent report by Hisaki et al., (1994b) has 
also shown that in rat isolated lung, pressor responses to ET-1 were not influenced by 
phosphoramidon. Secondly, ETs could be releasing some bronchodilator substance 
resulting in a physiological antagonism, as reported by Uchida et al., (1991). In the
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present study, use of the selective ETa receptor antagonist BQ123, or a mixed ETa/ ETb 
receptor antagonist PD 145065, significantly augmented the bronchoconstrictor response 
of ET-1. This could indicate that activation of ETA receptors may release a 
bronchodilator substance which antagonizes the bronchoconstrictor response of ET-1. 
Interestingly, Battistini et a l, (1994) also reported that BQ123 potentiated the ET-1 
induced contractions of isolated guinea pig trachea. It has recently been shown that ET-1 
increased the levels of cAMP in cloned rat alveolar epithelial cells and these effects were 
blocked by the ETA receptor antagonist BQ123 (Markewitz et al., 1995).
Perfusion with the mixed ETA /  ETB receptor antagonists bosentan, or PD 145065, 
produced a significant reduction in the bronchoconstrictor responses of SX6C without 
having any effect on ET-l-induced responses. This could indicate that in bronchial 
smooth muscles the ETB2 receptors activated by ET-1 are different to the ETB2 receptors 
activated by SX6C. The existence of different ETB receptor sub-types in the isolated 
guinea-pig trachea has also been suggested by Battistini et a l, (1993) and Yoneyama et 
al., (1995). Alternatively, the strong binding affinity of ET-1 for ETB receptors may 
explain this discrepancy (Takasuka et al., 1992; Wu-Wong et al., 1994; Wu-Wong, et 
a l, 1995).
The cyclooxygenase inhibitor indomethacin did not alter the pulmonary vascular or 
bronchial actions of ET-1 or SX6C. This suggests that the effects of ETs or SX6C were 
not mediated or modulated by eicosanoids. Similar findings have been reported in other 
rat lung preparations (ODonnell et a l, 1990; Raffestin et a l, 1991; Barnard et a l, 1991; 
Rodman et a l,  1992). The present results also support the findings in human pulmonary 
vascular and bronchial tissues (McKay et a l, 1991).
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4.3 Modulation of lung responses to ETs in the presence of the nitric oxide synthase 
(NOS) inhibitor nitro-L-arginine (L-NOARG) under basal conditions
4.3.1 Pulmonary vascular actions
The pulmonary vasculature has a low basal tone. In order to determine if constant release 
of nitric oxide is responsible for this, the effect of the nitric oxide synthase inhibitor L- 
NOARG was studied at a concentration reported to block constitutive NOS (Moore et 
al., 1990). The results showed that L-NOARG had no effect on basal PPP, lung weight, 
or PIP suggesting that NO is not a major factor contributing to the low basal tone. These 
findings are in agreement with reports in other rat perfused lung preparations (Barer et 
al., 1993; Hampl et al., 1993; Hassessian and Bumstock, 1995).
ET-1 and SX6C -induced pulmonary vascular and bronchial actions were also studied in 
the presence of L-NOARG. The results show that L-NOARG markedly augmented the 
vasoconstrictor responses to ET-1 and SX6C. In contrast L-NOARG did not alter the 
responses to PHE suggesting that it is not producing non-selective effects. Potentiation 
of ET-l-induced vasoconstriction in the presence of NOS inhibition has also been 
reported in other perfused rat lung preparations (Raffestin et al., 1991; Eddahibi et al., 
1991). In rat isolated pulmonary arteries potentiation of ET-l-induced contractions in 
the presence of a NOS inhibitor was reversed after the removal of the endothelium 
(MacLean et al., 1994).
A possible explanation of this potentiation is that ET-1 and SX6C release endogenous 
nitric oxide via activation of the endothelial ETBi receptors (Douglas et al., 1994 ). 
Inhibition of this process with L-NOARG would result in potentiation of 
vasoconstriction mediated via ETA and ETB2 receptors located on the vascular smooth 
muscle. Another possible explanation is that under normal circumstances basally released 
endogenous nitric oxide suppresses the vasoconstrictor responses to these agonists. 
However, in this model results suggests that NO is not a major factor contributing to the
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low basal vascular tone because (a) L-NOARG had no effect on basal pulmonary 
vascular tone, (b) L-NOARG did not potentiate PHE responses.
In the presence of L-NOARG the increases in PPP induced by SX6C were far greater 
than those induced by ET-1. This may be due to the fact SX6C being a selective ETB 
receptor agonist (Williams et al., 1991) is more potent in releasing nitric oxide, therefore 
in presence of NOS inhibitor its effects would be potentiated more as compared to the 
non-selective ET receptor agonist such as ET-1 (Arai et al., 1990; Sakurai et al.,. 1990).
L-NOARG also potentiated BK-induced increases in PPP suggesting that BK, like ET-1 
and SX6C, also stimulates the endogenous production of nitric oxide. This is in 
agreement with reports showing that BK-induces endothelium-dependent relaxation of 
pulmonary blood vessels (Feletou et al., 1995; Gao et al., 1995b).
4.3.2 Lung weight
L-NOARG also potentiated lung weight increases in response to ET-1 or SX6C 
suggesting that evoked release of nitric oxide inhibits pulmonary oedema in response to 
these agonists. Responses to ET-1 and SX6C in the absence of L-NOARG suggested 
that the increases in lung weight were due to their venoconstrictor actions leading to 
hydrostatic oedema. Therefore one possibility which could explain lung weight increases 
in the presence of L-NOARG is an augmented vasoconstrictor response which would 
cause a hydrostatic increase in lung weight. The second possibility is that nitric oxide 
causes preservation of endothelial barrier functions to prevent extravasation (Zi-Qiang et 
al., 1994). The fact that L-NOARG potentiated the vasoconstrictor responses to BK 
without altering its effects on lung weight suggests that the second possibility may be 
unlikely. However, in the presence of L-NOARG, albumin-bound dye extravasation in 
response to ET-1, SX6C and BK was not examined and this would need further 
investigation.
In the presence of L-NOARG the potency of SX6C to increase lung weight was greater 
than ET-1, whereas it produced little increase in lung weight in the absence of L- 
NOARG. This further supports the suggestion that SX6C is more potent in releasing 
nitric oxide than ET-1. The fact that L-NOARG potentiated lung weight responses to 
SX6C may indicate the presence of small population of ETB2 receptors on the venous 
smooth muscle and that venoconstriction mediated via these receptors was masked by 
the release of nitric oxide. Zellers et al., (1994) have reported that the ETs and SX6C - 
induced release of vasodilators is greater in porcine pulmonary veins than arteries. Gao et 
al., (1995a) have also shown that endothelium-derived nitric oxide plays a larger role in 
neonatal lamb pulmonary veins than pulmonary arteries, which they suggested may be 
due to differences in the activity of guanylate cyclase in venous smooth muscle. The 
present studies do not provide any evidence for the site of release or action of nitric 
oxide in this model. Further experiments using retrograde perfusion in the presence of L- 
NOARG would be needed to understand the mechanisms involved in the vascular actions 
of ET-1, SX6C and BK.
4.3.3 Bronchial actions c.
ET-1- and SX6C- induced bronchoconstriction was also potentiated by L-NOARG 
suggesting that evoked release of nitric oxide was inhibiting their bronchial constrictor 
actions. Because nitric oxide is a diffusible gas (Butler et al., 1995) it is possible that 
induced release of nitric oxide from the vascular endothelium could pass to the bronchial 
smooth muscle to reduce the ET-1 or SX6C induced responses. However, this is 
unlikely, because L-NOARG augmented the vasoconstriction caused by BK but had no 
significant effect on its bronchoconstrictor responses. Alternatively, ET-1 or SX6C could 
release nitric oxide from the bronchial and alveolar epithelium via activation of ETB 
receptors which in turn would reduce the bronchoconstrictor effects of these agonists.
In support of this, investigators, have reported the presence of NOS in the airway 
epithelium in rat lungs (Xue et al., 1994). Previous studies have also shown that ET-1 
can produce relaxation of precontracted guinea pig trachea (Uchida et al., 1991;
Battistini et al., 1994). In addition the contractile effects of ETs on the isolated guinea 
pig bronchus were also potentiated after the removal of epithelium (Maggi et al., 1990). 
The bronchoconstrictor effects of SX6C in the presence of L-NOARG were potentiated 
to a greater extent compared to effects of ET-1. This may be due to the fact that SX6C 
is more potent in releasing nitric oxide. Alternatively ET-1 may be releasing some 
weaker bronchodilator component(s) which attenuate its constrictor effects on the 
airway smooth muscle. Recently, Markewitz et al., (1995) reported that rat alveolar 
epithelial cells posses a novel ETA receptor subtype which on stimulation with ET-1 
increases cAMP levels in these cells. Therefore it is possible that in this model such a 
mechanisms would suppress the bronchoconstrictor effects of ET-1 but not SX6C. The 
fact that L-NOARG had no effect on the bronchoconstrictor responses to BK or CCh 
suggests that neither of these agonists stimulates NO production by the respiratory 
epithelium.
Effects of ETs and SX6C were also examined when the basal vascular tone was elevated 
by infusion of U46619. The infusion of very low amounts produced concentration- 
dependent increases in PPP, lung weight and PIP. Interestingly, when the infusioaof 
U46619 was stopped, the increased PPP and lung weight were rapidly reversible. This 
may indicate that U46619 predominantly produced venoconstriction which resulted in 
hydrostatic pulmonary oedema. However, further experiments utilising retrograde 
perfusion in the presence of U46619 would be needed to study this phenomenon.
4.4 Vasodilation andET receptor antagonists
In the U46619 preconstricted preparations very low doses of ET-1, ET-3 and SX6C 
produced dose-dependent falls in PPP. The results support the findings in other rat 
perfused lung preparations (Eddahibi et al., 1993; Eddahibi et al., 1995). The fact that 
ET-1 was equipotent with ET-3 in producing vasodilation, whereas, the highly selective 
ETb receptor agonist SX6C (Williams et al., 1991) was significantly more potent 
suggests a role for ETBi receptors in these responses. This is supported by the
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observations that the ETA receptor antagonist BQ123 did not block the vasodilator 
response to ET-1, whereas, a mixed ETA / ETB receptor antagonist bosentan completely 
abolished the dilator responses to ET-1 and SX6C. Similar findings have been reported 
in other rat lung preparations (Eddahibi et al., 1993; Eddahibi et al., 1995). The present 
results are also in agreement with in vivo reports in rat (Clozel et al., 1992; Clozel et al., 
1994). BQ123 augmented the fall in PPP produced at the highest (40 pmol) dose of ET- 
1, however, responses to lower doses were not altered. This suggests that at higher 
doses of ET-1 ETA receptors are activated and this causes a physiological antagonism of 
the ETBi-mediated vasodilation. Potentiation of ET-l-induced pulmonary vasodilation in 
the presence of BQ123 has also been reported in lungs from new bom piglet (Perreault 
and Baribeau, 1995) and in isolated porcine pulmonary vessels (Zellers et al., 1994). The 
fact that bosentan had no effect on the vasodilatation caused by sodium nitroprusside, 
suggests that it is not having a non-selective action on cyclic GMP production.
4.5 Tachyphylaxis and cross-tachyphylaxis
Repeated injections of a single dose of ET-1 or SX6C (20 pmol) caused a rapid loss of 
pulmonary vasodilator responses indicating desensitization. Investigators have reported a 
similar phenomenon in vivo in cats (Le Monnier De Gouville et al., 1990; Lippton et a l, 
1993; Ekelund et al., 1994) and in rat basilar artery (Kitazono et al., 1995). Results have 
shown that repeated administration of these agonists desensitized only the vasodilator 
responses, whereas vasoconstriction to both the agonists was still seen. Furthermore, 
under basal conditions activation of ETB receptors resulted in vasoconstriction. This 
provides evidence of a functionally distinct ETB receptor populations in the rat 
pulmonary vascular bed i.e. ETBi receptors located on the endothelium which mediate 
vasodilatation whereas ETB2 receptors located on the smooth muscle are responsible for 
the vasoconstrictor action (Shetty et al., 1993). These findings are in agreement with the 
recently reported ETB receptor subtypes in new bom piglet lungs (Perreault and 
Baribeau, 1995). In ET-1 desensitized lungs further injections of very low doses of 
SX6C also failed to cause vasodilatation, instead it produced a dose-dependent
vasoconstriction. Similarly in lungs desensitized with SX6C further injections of low 
doses of ET-1 failed to produce any vasodilatation, and a dose- dependent 
vasoconstriction was seen. This suggests the development of cross-tachyphylaxis to the 
vasodilator actions of ET-1 and SX6C.
Several possibilities could explain the cross-tachyphylaxis phenomenon seen in this 
model. First, ET-1 and SX6C may stimulate a single type of receptor that becomes 
rapidly refractory to activation by these peptides. Alternatively, ET-1 and SX6C could 
bind to distinct receptor sites which share at least one common point in the second 
messenger system. This shared portion of the reaction chain may then becomes impaired 
or refractory, after repeated stimulation of the receptors. Consequently, all receptors 
using this common pathway to transform their membrane signal into a response will fail 
to evoke functional responses when activated by their agonists. Thus, for instance cross 
tachyphylaxis to ET-1 and SX6C may reflect the depletion of an endogenous vasodilator 
such as nitric oxide. Another possibility which could explain the tachyphylaxis 
phenomenon is that ETbi receptors may get internalised thus reducing the receptor 
population available for mediating vasodilation. d
4.6 Vasodilation and inhibitors
In the U46619 precontracted preparations indomethacin did not affect SX6C-induced 
vasodilation but it did reduce the vasodilator effects of low doses of ET-1. However, 
responses to the higher doses were not significantly altered. This suggests that ET-1 
induced vasodilatation is partially mediated by the release of vasodilator prostanoids. 
Vasodilator actions of ETs have been shown to be partially blocked by indomethacin in 
vivo in cats (Ekelund et al., 1994), while DeNucci et al., (1988) have also shown ET-1 
stimulated prostacyclin synthesis in rat lungs.
The possible role of nitric oxide in the ET-1- and SX6C-induced pulmonary vasodilation 
was evaluated using L-NOARG. The fact that L-NOARG potentiated the pressor
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responses to U46619 suggesting that U46619 also evoked endogenous production of 
nitric oxide in the rat pulmonary circulation. Similar findings have been reported in lungs 
from neonatal pigs (Pinheiro and Malik, 1993). Therefore, in lungs treated with L- 
NOARG a lower concentration of U46619 had to be used in order to elevate the PPP (= 
9mmHg) to a similar level seen in the absence of L-NOARG.
L-NOARG blocked the vasodilatation induced by the higher doses of ET-1, whereas, 
responses to lower doses of ET-1 were not altered. D-NOARG was without effect. 
Vasodilator responses to ET-1 were completely abolished by the presence of both 
indomethacin and L-NOARG. This suggests that the vasodilator actions of ET-1 in rat 
pulmonary circulation are mediated by the release of both nitric oxide and prostanoids. 
Similar findings have been reported in porcine pulmonary blood vessels (Zellers et al.,
1994) and perfused lungs (Pinheiro and Malik, 1993). The finding that L-NOARG alone 
completely abolished the vasodilatation caused by SX6C, whereas D-NOARG did not 
alter these responses indicates that the dilator effects of SX6C are mediated exclusively 
by nitric oxide production. The present findings are in agreement with studies using 
isolated pulmonary arteries (Namiki et al., 1992). However, these finding are not in 
agreement with the observations of Eddahibi et al., (1993) who also used perfused rat 
lung. This may be due to different experimental conditions, or the use of a different NOS 
inhibitor, L- N°- monomethyl arginine (L-NMMA) which has been reported to 
selectively inhibit basal release of nitric oxide without affecting the agonist-evoked 
release (Frew et al., 1993). These workers also used the guanylate cyclase inhibitor 
methylene blue to show that ETs vasodilation is not due to cyclic GMP generation 
caused by nitric oxide, however, it has been shown that nitric oxide can cause smooth 
muscle relaxation independent of guanylate cyclase activation (Bolotina et al., 1994). 
The fact that L-NOARG had no effect on the vasodilator actions of the nitric oxide 
donor sodium nitropmsside suggests that L-NOARG is not having a non-selective action 
on cGMP generation.
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In summary the present experiments have shown that activation of both ETA and ETB2 
receptors can lead to constriction in the pulmonary vascular bed. In addition, evidence is 
provided to show that ETA receptors are predominantly present on the venous side of the 
pulmonary circulation whereas ETB2 receptors are located arterially. The changes in lung 
weight in responses to ETs probably reflects hydrostatic oedema resulting from intense 
venoconstriction. Results also suggest the possibility of heterogeneity of ETA and ETB2 
receptor subtypes. Furthermore, it has been shown that under basal conditions 
endogenous release of nitric oxide modulates the pulmonary vascular and bronchial 
actions of ETs and SX6C. The pulmonary vasodilator actions of ETs are mediated by the 
activation of ETB1 receptors and involve endogenous release of nitric oxide. Results have 
also shown the tachyphylaxis to the pulmonary vasodilator actions of ET-1 and SX6C.
A simple ventilated perfused rat lung model has been used to study the actions of variety 
of substances which exert selective actions on the pulmonary vascular or bronchial 
smooth muscle. Furthermore, by studying dye accumulation associated with manipulation 
of VOP, or injections of vasoactive agents with orthograde or retrograde perfusion, 
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Appendix-n
Abbreviations
ANOVA analysis of variance
ANP atrial natriuretic peptide
Arg arginine
ARDS adult respiratory distress syndrome
Asp aspartic acid
BK bradykinin
BSA bovine serum albumin
CCh carbachol
cAMP cyclic adenosine 3', 5' -monophosphate
cGMP cyclic guano sine monophosphate





EDCF endothelium-derived contracting factor
ECE endothelin converting enzyme
EDHF endothelium- derived hyperpolarizing factor











mRNA messenger ribonucleic acid
NANC non-adrenergic non-cholinergic
NO nitric oxide
NOS nitric oxide synthase





PIP pulmonary inflation pressure
PPP pulmonary perfusion pressure
Pro proline




U46619 9,11- Dideoxy-1 loc, 9X- epoxy-
methanoprostaglandin F2oc 
Val valine
VIP vasoactive intestinal peptide
VIC vasoactive intestinal contracting factor
VOP venous outflow pressure
